

# Childhood cancer survival in Australia, 1995-2004

Published October 2010



**VCRCC**  
Viertel Centre  
for Research in Cancer Control

Accredited by the NHMRC as an independent research institute.

The generosity of the Queensland community and the *Sylvia and Charles Viertel Charitable Foundation* makes our research possible.

Cancer Council Queensland  
553 Gregory Terrace  
Fortitude Valley QUEENSLAND 4006  
AUSTRALIA

Postal Address:  
PO Box 201  
Spring Hill QUEENSLAND 4004  
AUSTRALIA

Telephone: +61 7 3634 5309  
Facsimile: +61 7 3259 8527  
Email: [research@cancerqld.org.au](mailto:research@cancerqld.org.au)  
Website: [www.cancerqld.org.au](http://www.cancerqld.org.au)

© Cancer Council Queensland

Copyright protects this publication. However, the Cancer Council Queensland has no objection to this material being reproduced with appropriate acknowledgment, except for commercial purposes. Permission to reproduce for commercial purposes should be sought from the Public Relations Manager, Media and Advocacy, Cancer Council Queensland.

ISBN: 978-1-876360-16-0

**Suggested citation:** Youlden D, Baade P, Ward L, Valery P, Hassall T, Green AC, Aitken JF, 2010. *Childhood cancer survival in Australia, 1995-2004*. Viertel Centre for Research in Cancer Control, Cancer Council Queensland and the Australian Paediatric Cancer Registry: Brisbane, Queensland.

#### Acknowledgements:

The work of staff at all Australian State and Territory Cancer Registries, the Australian Institute of Health and Welfare and the Medical Records department at each of the paediatric oncology treating hospitals listed below is acknowledged and appreciated. Without their support and dedication, this report would not have been possible.

Queensland Cancer Registry  
New South Wales Cancer Registry  
Australian Capital Territory Cancer Registry  
Victorian Cancer Registry  
Tasmanian Cancer Registry  
South Australian Cancer Registry  
Northern Territory Cancer Registry  
Western Australia Cancer Registry

Royal Children's Hospital (Qld)  
Mater Children's Hospital (Qld)  
Sydney Children's Hospital (NSW)  
The Children's Hospital at Westmead (NSW)  
John Hunter Hospital (NSW)  
Royal Children's Hospital (Vic)  
Monash Medical Centre (Vic)  
Royal Hobart Hospital (Tas)  
The Women's and Children's Hospital (SA)  
The Princess Margaret Hospital (WA)

Australian Institute of Health and Welfare

The authors also wish to thank the review panel for their expert critique of the report:

- Ms Josepha Dietrich, Patient Advocate, Cancer Voices Queensland.
- Ms Yvette Hidding, Parent Representative, Cancer Network (CanNET) Tasmania.
- Prof Ross Pinkerton, Staff Specialist Paediatric Oncology and Director of Cancer Services, Royal Children's and Mater Children's Hospitals, Brisbane.
- Ms Chris Sturrock, Unit Head, Cancer and Screening Unit, Australian Institute of Health and Welfare, Canberra.
- Prof Alison Venn, Director, Tasmanian Cancer Registry and Chair, Australasian Association of Cancer Registries, Hobart.

Dr William R McWhirter, Prof Ian Ring and Mrs Cecily Dobson are acknowledged and thanked for their valuable contribution to the establishment and early work of the Australian Paediatric Cancer Registry.

The front cover was designed by Ms Soraya Franklin, Creative Services, Cancer Council Queensland.



## Table of Contents

<b>Foreword</b> .....	<b>iv</b>
<b>Executive Summary</b> .....	<b>v</b>
<b>1 Introduction</b> .....	<b>1</b>
1.1 Background information .....	1
1.2 The Australian Paediatric Cancer Registry .....	1
1.3 Classification of childhood cancers .....	2
1.4 Overview of this report.....	2
<b>2 Survival for all childhood cancers combined</b> .....	<b>4</b>
<b>3 Survival by childhood cancer diagnostic group</b> .....	<b>7</b>
3.1 Leukaemias, myeloproliferative diseases and myelodysplastic diseases .....	7
3.2 Lymphomas and reticuloendothelial neoplasms .....	10
3.3 Central nervous system and miscellaneous intracranial and intraspinal neoplasms .....	13
3.4 Neuroblastoma and other peripheral nervous cell tumours .....	16
3.5 Retinoblastoma.....	19
3.6 Renal tumours .....	21
3.7 Hepatic tumours .....	24
3.8 Malignant bone tumours .....	26
3.9 Soft tissue and other extraosseous sarcomas .....	29
3.10 Germ cell tumours, trophoblastic tumours and neoplasms of gonads .....	32
3.11 Other malignant epithelial neoplasms and melanomas .....	35
<b>Appendix</b> .....	<b>38</b>
A.1 Codes for childhood cancer diagnostic groups .....	38
A.2 Data.....	41
A.3 Methods.....	42
A.4 Detailed estimates of survival for childhood cancer diagnostic subgroups .....	44
<b>References</b> .....	<b>48</b>

## Foreword

The Australian Paediatric Cancer Registry (APCR) is one of the few national registers of childhood cancer in the world. Funded and managed by Cancer Council Queensland, and with appropriate ethical and legislative approvals, the APCR records clinical and treatment information on every child diagnosed with cancer in Australia.

This report, the second from the APCR in the current series, provides detailed information on survival for children in Australia following a diagnosis of cancer. It is pleasing to note that overall five-year relative survival for children with cancer is now close to 80%, a significant increase since the early 1980s. In particular, marked improvements in survival have been achieved for children diagnosed with leukaemia, lymphoma and neuroblastoma. We trust that the gains in survival and quality of life that have occurred over recent decades will continue as further developments in treatment occur.

Accurate and timely data collection is a key priority for the APCR. This has been made possible only through the support and assistance of all State and Territory Cancer Registries and all treating paediatric oncology hospitals throughout Australia. I would like to express my personal thanks to the staff involved who have given their time and energy to support this national data collection.

Finally and most importantly, we acknowledge the children and their families who are represented in this report. We hope that the information contained herein will contribute to the campaign to improve outcomes for childhood cancer and provide another step towards a cancer-free future.



Professor Jeff Dunn  
Chief Executive Officer  
Cancer Council Queensland

## Executive Summary

More than 600 children aged 0-14 years old are diagnosed with cancer each year in Australia. Advances in therapy have resulted in widespread improvements in survival for childhood cancer patients in recent years. However, cancer remains as one of the leading causes of death within this age group and many survivors face serious long term adverse health effects, caused by either the cancer itself or as a result of treatment.

This report describes the latest population-based survival estimates for children diagnosed with cancer in Australia using data from the Australian Paediatric Cancer Registry (APCR). The APCR is a valuable resource, as it is one of the few national registries of childhood cancer in the world. Population-based survival studies are essential for providing robust indicators to evaluate the effectiveness of healthcare provision and to monitor progress in cancer control at a national level.

Five-year relative survival for all children diagnosed with cancer in Australia during 1995-2004 was 79.5%. Significant variation was observed in survival according to diagnostic group, with 5-year relative survival ranging from 68.4% for children with neuroblastoma up to 99.1% for those with retinoblastoma.

Only minor differences were observed in survival by sex for most types of childhood cancer, except for leukaemia, for which girls (83.5%) had a significantly higher rate of 5-year relative survival compared to boys (78.1%).

Infants (aged less than 1 year old at diagnosis) tended to have poorer survival than other children with cancer. This pattern was particularly evident for leukaemias and tumours of the central nervous system. However, the reverse was true for neuroblastoma and hepatic tumours, with a decrease in survival as age at diagnosis increased.

Within the diagnostic groups where information on staging was available (lymphomas, neuroblastoma, renal tumours and the diagnostic subgroup of rhabdomyosarcomas), there was a consistent trend towards a decrease in survival as stage at diagnosis progressed. For example, among children with neuroblastoma, 5-year relative survival dropped from 95.6% for stage I tumours to 49.8% for stage IV tumours.

Five-year relative survival for all childhood cancers combined increased from 72.3% for the years 1983-1994 to 79.5% during 1995-2004. Significant improvements in survival for children who were diagnosed more recently were recorded for leukaemias (increase from 69.1% during 1983-1994 to 80.6% during 1995-2004), lymphomas (80.8% to 89.6%) and neuroblastoma (52.9% to 68.4%). In contrast, there was a significant decrease in 5-year relative survival within the diagnostic subgroup of non-rhabdomyosarcoma soft tissue sarcomas, declining from 84.5% to 72.5% between 1983-1994 and 1995-2004.

Survival for all childhood cancers combined and for the various diagnostic groups was generally similar in Australia to corresponding estimates from other developed countries including the United States, Great Britain and France.

Despite the improvement in survival for children in Australia with cancer, about 20% of those who are diagnosed will still die within 5 years. In the future, it is hoped that developments in treatment protocols through large multi-centre studies, particularly advances in the ability to tailor treatments for individual patients and tumours, will lead to further increases in survival rates while at the same time improving longer term quality of life for childhood cancer survivors.



## 1 Introduction

### 1.1 Background information

More than 600 children under 15 years of age are diagnosed with cancer each year in Australia<sup>1</sup> and on average around 100 children die from cancer annually.<sup>2</sup> Thus, although cancer is relatively rare among children compared to people in the older age groups, it is still the most common cause of disease-related death for children aged 1-14 years old in Australia.<sup>3</sup>

Survival after a diagnosis of cancer is dependent on a number of factors such as early detection and access to appropriate and co-ordinated treatment services.<sup>3</sup> The main treatments for children with cancer include surgery, chemotherapy and radiotherapy.<sup>4</sup> Chemotherapy tends to be particularly effective because it targets fast-growing cells which are typical in many forms of childhood cancer. Ongoing advances in the treatments available and their application have led to large improvements in survival for childhood cancer over the last few decades. Most of these breakthroughs have come about as a direct result of collaborative clinical trials.<sup>5,6</sup>

This positive news is tempered by the knowledge that some of the children who survive may experience long term adverse health effects, either because of the cancer itself or as a result of treatment. The medical issues faced by survivors of childhood cancer can include increased risk of subsequent cancer, organ dysfunction (cardiopulmonary, renal, gastrointestinal), impaired growth and development, decreased fertility and neurocognitive deficits.<sup>7,8</sup>

Nonetheless, survival estimates are a key indicator of success in cancer control. Clinical trials can only report on outcomes for a selected group of patients, rather than indicating the overall survival experience for all people with cancer in a particular region or country. Population-based survival studies such as this are therefore an important part of evaluating the effectiveness of treatment services for childhood cancer patients at a national level.

### 1.2 The Australian Paediatric Cancer Registry

The Australian Paediatric Cancer Registry (APCR) is one of only a few population-based national registries of childhood cancer in the world. Information is collected on incidence, survival, treatment and stage at diagnosis (where available) for all children in Australia who are diagnosed with cancer between the ages of 0-14 years. While details on cancer incidence and survival by age group are available from each individual State and Territory Cancer Registry, these registries do not collect data on the stage of disease or the treatment given to children with cancer. This information is essential in order to set and measure standards of care for children with cancer and to track improvements in treatment outcomes over time.

Notification of invasive cancer is a statutory requirement for all public and private hospitals, nursing homes and pathology services in Australia. With the appropriate ethical and legislative approvals, the APCR collects clinical and demographic information about all cases of childhood cancer from the State and Territory Cancer Registries and directly from the major treating hospitals. A comprehensive quality assurance process is used. Registry records are cross-checked against hospital records to resolve any inconsistencies or differences in the information collected. Strict protocols are in place to ensure the privacy and confidentiality of all information stored on the APCR database.

Cancer Council Queensland (CCQ), formerly known as the Queensland Cancer Fund, has provided financial support for the APCR since its inception in 1977. The APCR was transferred to Brisbane from Sydney in 1983, and in 2004 CCQ took over its management.

Currently there are 24 years of detailed and verified data available from the APCR (1983 to 2006), involving approximately 14,000 cases.

### 1.3 Classification of childhood cancers

There are several important differences between childhood and adult cancers, such as how the cancer originates and various clinical characteristics.<sup>9</sup> Many childhood cancers develop as a result of abnormal cell maturation; therefore, the tissue of origin, rather than the location in the body where the cancer starts, is the best predictor of tumour behaviour, prognosis and the required treatment. Childhood cancers are consequently classified using a different coding system to adult cancers, with categories based on the type of cancer tissue (morphology) instead of where the cancer occurs in the body.<sup>10,11</sup>

The third edition of the International Classification of Childhood Cancers (ICCC-3), the current standard for reporting childhood cancer, comprises 12 major diagnostic groups and 47 subgroups<sup>10</sup> (Table 1). Full details of the codes for each diagnostic group and subgroup are included in Appendix Table A.1, page 38.

**Table 1 International Classification of Childhood Cancers, 3<sup>rd</sup> edition (ICCC-3) Diagnostic Groups**

Diagnostic Group	Full title	Abbreviated title used in this report
I.	Leukaemias, myeloproliferative diseases and myelodysplastic diseases	Leukaemias
II.	Lymphomas and reticuloendothelial neoplasms	Lymphomas
III.	Central nervous system and miscellaneous intracranial and intraspinal neoplasms	Tumours of the central nervous system
IV.	Neuroblastoma and other peripheral nervous cell tumours	Neuroblastoma
V.	Retinoblastoma	Retinoblastoma
VI.	Renal tumours	Renal tumours
VII.	Hepatic tumours	Hepatic tumours
VIII.	Malignant bone tumours	Malignant bone tumours
IX.	Soft tissue and other extraosseous sarcomas	Soft tissue sarcomas
X.	Germ cell tumours, trophoblastic tumours and neoplasms of gonads	Germ cell tumours
XI.	Other malignant epithelial neoplasms and melanomas	Other malignant epithelial neoplasms and melanomas
XII.	Other and unspecified malignant neoplasms	Other malignant neoplasms

Source: Steliarova-Foucher et al, 2005.<sup>10</sup>

Most of the cases of childhood cancer included in this report are malignant (or invasive) neoplasms. Although tumours of benign or uncertain behaviour are generally not included in cancer registry data for adults, the ICCC-3 includes non-malignant intracranial and intraspinal tumours within diagnostic groups III and X due to similarities in their clinical symptoms and prognosis compared to the corresponding malignant tumours.<sup>10</sup> **Therefore, throughout this report, childhood cancer refers to all malignant neoplasms as well as intracranial and intraspinal tumours of benign or uncertain behaviour within the diagnostic groups “Tumours of the central nervous system” and “Germ cell tumours”.** Other non-invasive tumours (e.g. in situ melanomas) are not part of the international standard, and hence have been excluded from all data shown in the report.

Due to the small number of cases in diagnostic group XII (“Other malignant neoplasms”), no further analysis was undertaken nor detailed results presented for this group.

### 1.4 Overview of this report

This report provides a comprehensive analysis of population-based survival outcomes for children with cancer throughout Australia based on data contained in the APCR. It is a companion document to a report titled “Childhood cancer incidence in Australia, 1983-2006”<sup>1</sup> which was published in December 2009. Copies of both reports are available on request from the Viertel Centre for Research in Cancer Control at Cancer Council Queensland (research@cancerqld.org.au). They can also be downloaded from the CCQ website by visiting “www.cancerqld.org.au/page/Research\_statistics/VCRCC/Statistical\_reports”.

The main focus of this report is on the survival of all children diagnosed with cancer in Australia during 1995-2004, with follow-up to 31<sup>st</sup> December 2006. Estimates are expressed in terms of relative survival, which adjusts the observed rate of survival among children with cancer by the underlying survival of all children in the general population, and were calculated using the cohort method, with an emphasis on 5-year survival (see Appendix A.3.3, page 43, for further details on survival methodology).

Survival data are presented for all cancers combined and for each diagnostic group by time since diagnosis, sex and age group at diagnosis. Where possible, the age groups used were <1 year, 1-4 years, 5-9 years and 10-14 years. However, these age groups were collapsed if there was insufficient data to calculate reliable survival estimates. For example, children aged <1 year and 1-4 years were combined into the 0-4 age group for the diagnostic groups of lymphomas and soft tissue sarcomas.

Within the various diagnostic groups, survival estimates were also calculated for the major subgroups and by stage, which provides an indication of how advanced the cancer was at diagnosis. (Information on stage was only available for certain cancers, including lymphomas, neuroblastoma, renal tumours and the diagnostic subgroup of rhabdomyosarcomas within soft tissue sarcomas.) In addition, changes in survival over time were examined by comparing the survival of children diagnosed during 1995-2004 with children diagnosed in the period 1983-1994. Finally, the survival of childhood cancer patients in Australia was benchmarked against corresponding international estimates.

Throughout the report, a measure known as the “p-value” has been used to determine whether survival estimates are different to each other in a statistical sense. P-values have a range of 0 to 1; the smaller the p-value, the greater the likelihood that any variation has not occurred by chance alone. In particular, a p-value of less than 0.05 indicates that the difference between survival estimates is statistically significant.


Information on the definitions for the diagnostic groups and subgroups, as well as an explanation of the statistical terminology and methods (including the calculation of p-values), can be found in the Appendix.

## 2 Survival for all childhood cancers combined

### Survival by time since diagnosis

Most of the deaths among children with cancer occurred in the first few years following diagnosis. Relative survival for all cancers combined was 90.4% by the end of the first year after diagnosis compared to 79.5% after 5 years, then slowly decreased to 77.2% after 10 years (Box 2a).

**Box 2a: Relative survival by time since diagnosis for all childhood cancers (n=6,177)<sup>a</sup>, Australia, 1995-2004<sup>b</sup>**



### Survival by diagnostic group

Highly significant differences existed for 5-year relative survival between the childhood cancer diagnostic groups (Box 2b). Survival was highest for retinoblastoma (99.1%), other malignant epithelial neoplasms and melanomas (93.0%), germ cell tumours (90.5%), lymphomas (89.6%) and renal tumours (89.2%), while survival was lowest for neuroblastoma (68.4%), malignant bone tumours (69.5%), soft tissue sarcomas (70.6%) and tumours of the central nervous system (70.8%).


**Box 2b: Five-year relative survival for all childhood cancers by diagnostic group, Australia, 1995-2004<sup>a</sup>**

Diagnostic group	Number of cases <sup>b</sup>	Five-year relative survival (95% CI) <sup>c</sup>
I. Leukaemias	2,036	80.6 (78.7-82.3)
II. Lymphomas	607	89.6 (86.8-91.8)
III. Tumours of the central nervous system (CNS) <sup>d</sup>	1,406	70.8 (68.3-73.2)
IV. Neuroblastoma	367	68.4 (63.3-73.0)
V. Retinoblastoma	159	99.1 (95.4-100.0)
VI. Renal tumours	328	89.2 (85.2-92.2)
VII. Hepatic tumours	93	77.3 (67.1-84.7)
VIII. Malignant bone tumours	263	69.5 (63.2-75.0)
IX. Soft tissue sarcomas (STS)	333	70.6 (65.2-75.3)
X. Germ cell tumours <sup>d</sup>	244	90.5 (86.0-93.7)
XI. Other malignant epithelial neoplasms & melanomas	324	93.0 (89.4-95.4)

*p* < 0.001

(Continued next page...)

**Box 2b (cont.): Five-year relative survival for all childhood cancers by diagnostic group, Australia, 1995-2004<sup>a</sup>**



Notes: a. Cohort includes children diagnosed during 1995-2004 with follow-up to 31 Dec 2006.  
 b. The initial number of eligible cases in the cohort.  
 c. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).  
 d. Diagnostic group includes intracranial and intraspinal tumours of benign or uncertain behaviour.


Survival by sex

Relative survival for all cancers combined was slightly, but significantly, higher for girls (80.8% after 5 years) compared to boys (78.4% - Box 2c). This appeared to be mainly due to the higher survival rate for girls with leukaemia (see Box 3.1c).

**Box 2c: Five-year relative survival for all childhood cancers by sex, Australia, 1995-2004<sup>a</sup>**

Sex	Number of cases <sup>b</sup>	Five-year relative survival (95% CI) <sup>c</sup>
Boys	3,363	78.4 (77.0-79.8)
Girls	2,814	80.8 (79.2-82.2)
		<i>p</i> = 0.022

Notes: a. Cohort includes children diagnosed during 1995-2004 with follow-up to 31 Dec 2006.  
 b. The initial number of eligible cases in the cohort.  
 c. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).



Survival by age group at diagnosis

Infants (under 1 year of age) had significantly poorer survival for all cancers combined compared to other children. Five-year relative survival varied from 75.1% for children less than 1 year old to around 80% for those in the 1-4, 5-9 and 10-14 age groups (Box 2d). Again, this result was likely to be heavily influenced by variation in survival for leukaemia by age at diagnosis (see Box 3.1d). Survival for all cancers combined may also be affected by the mix of cancers that are most commonly diagnosed within a particular age group. For example, the majority of neuroblastoma, retinoblastoma, renal tumours and hepatic tumours occur before 4 years of age, whereas malignant bone tumours and other malignant epithelial neoplasms are more common in the 10-14 age group.<sup>1</sup>

**Box 2d: Five-year relative survival for all childhood cancers by age group at diagnosis, Australia, 1995-2004<sup>a</sup>**

Age group at diagnosis	Number of cases <sup>b</sup>	Five-year relative survival (95% CI) <sup>c</sup>
< 1 year	606	75.1 (71.4-78.4)
1-4 years	2,231	80.2 (78.5-81.9)
5-9 years	1,569	79.2 (77.0-81.2)
10-14 years	1,771	80.3 (78.3-82.2)

*p* = 0.009

Notes: a. Cohort includes children diagnosed during 1995-2004 with follow-up to 31 Dec 2006.  
 b. The initial number of eligible cases in the cohort.  
 c. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).

Survival by year of diagnosis

A significant improvement in survival over time was recorded among all children with cancer. Five-year relative survival increased from 72.3% for children diagnosed during 1983-1994 to 79.5% during 1995-2004 (Box 2e).

**Box 2e: Five-year relative survival for all childhood cancers by year of diagnosis, Australia, 1983-2004<sup>a</sup>**

Year of diagnosis	Number of cases <sup>b</sup>	Five-year relative survival (95% CI) <sup>c</sup>
1983-1994	6,398	72.3 (71.2-73.4)
1995-2004	6,177	79.5 (78.5-80.5)

*p* < 0.001

Notes: a. Cohorts include children diagnosed during 1983-1994 and 1995-2004 with follow-up to 31 Dec 2006.  
 b. The initial number of eligible cases in the cohort.  
 c. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).

International comparisons

Five-year survival for all childhood cancers in Australia (80%) was similar to recent results that have been published for the United States (80%), France and Great Britain (both 78% - see Box 2f). Estimates of overall childhood cancer survival during 1995-2002 for many other countries in Europe also ranged between 78% to 83% after 5 years.<sup>12</sup>

**Box 2f: Five-year survival for all childhood cancers in selected countries<sup>a</sup>**

Country	Years	Number of cases	Method	5-year survival (%) (95% CI) <sup>b,c</sup>
Australia	1995-2004	6,177	Relative survival – cohort method	80 (78-81)
France <sup>13</sup>	1995-1999	1,864	Observed survival – cohort method	78 (76-80)
Great Britain <sup>14</sup>	2001-2005	7,737	Observed survival – cohort method	78 (77-79)
United States <sup>15</sup>	1999-2006	18,286	Relative survival – cohort method	80 (79-81)

Notes: a. International comparisons should be treated with due caution – see Appendix A.2.3, page 42.  
 b. 95% CI = 95% confidence interval.  
 c. Survival estimates have been rounded to the nearest integer.

### 3 Survival by childhood cancer diagnostic group

#### 3.1 Leukaemias, myeloproliferative diseases and myelodysplastic diseases

##### Background


Leukaemias are cancers that arise from uncontrolled overproduction of abnormal white blood cells within the bone marrow. White blood cells are an important component of the immune system, and are involved in the body’s response to bacterial, viral and parasitic infection. However, in leukaemia patients, the presence of abnormal cells results in healthy blood cells being ‘crowded out’ of the bone marrow.

Most leukaemias which occur in children are acute, meaning that the cancerous cells are both immature and produced rapidly. Leukaemia is further classified according to the predominant type of white blood cells that are present: lymphoid cells or myeloid cells.<sup>9,16</sup> Lymphoid leukaemias are the most common subgroup, accounting for more than three-quarters (78.2%) of all cases of childhood leukaemia in Australia during 1995-2004, followed by acute myeloid leukaemias (16.2%).

The symptoms of leukaemia are mainly those of inadequate bone marrow function, such as tiredness, fever, pallor and easy bruising. Some children also experience bone pain as a result of increased bone marrow activity.<sup>7,9,16,17</sup>

##### Survival by time since diagnosis

By the end of the first year after diagnosis, relative survival for childhood leukaemia was 92.4%. Survival continued to decrease to 80.6% after 5 years before levelling out to 78.2% after 10 years (Box 3.1a).



##### Survival by diagnostic subgroup

Highly significant differences were found by diagnostic subgroup, with lymphoid leukaemia estimated to have a 5-year relative survival rate of 85.3% compared to 62.3% for acute myeloid leukaemia (Box 3.1b).

**Box 3.1b: Five-year relative survival for childhood leukaemias by diagnostic subgroup, Australia, 1995-2004<sup>a</sup>**

Diagnostic subgroup <sup>b</sup>	Number of cases <sup>c</sup>	Five-year relative survival (95% CI) <sup>d</sup>
LL	1,592	85.3 (83.3-87.0)
AML	329	62.3 (56.7-67.3)

*p* < 0.001

Notes: a. Cohort includes children diagnosed during 1995-2004 with follow-up to 31 Dec 2006.  
 b. LL = lymphoid leukaemias; AML = acute myeloid leukaemias.  
 c. The initial number of eligible cases in the cohort.  
 d. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).

Diagnostic subgroup	Relative survival (%)
LL	85.3
AML	62.3

Survival by sex

Girls with leukaemia had a significantly higher rate of survival compared to boys. Five-year relative survival was 83.5% among girls and 78.1% for boys (Box 3.1c). The difference in relative survival by sex was only significant for lymphoid leukaemias (88.2% after 5-years for girls compared to 82.7% for boys) with no disparity recorded for acute myeloid leukaemias (see Appendix Table A.4a, page 44).

**Box 3.1c: Five-year relative survival for childhood leukaemias by sex, Australia, 1995-2004<sup>a</sup>**

Sex	Number of cases <sup>b</sup>	Five-year relative survival (95% CI) <sup>c</sup>
Boys	1,094	78.1 (75.4-80.5)
Girls	942	83.5 (80.9-85.8)

*p* < 0.001

Notes: a. Cohort includes children diagnosed during 1995-2004 with follow-up to 31 Dec 2006.  
 b. The initial number of eligible cases in the cohort.  
 c. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).

Sex	Relative survival (%)
Boys	78.1
Girls	83.5

Survival by age group at diagnosis

There was a large amount of variation in survival by age group for childhood leukaemia (Box 3.1d). Relative survival was significantly lower among children under 1 year old (53.6% after 5 years), but increased sharply for children diagnosed between the ages of 1-4 (86.2%), before successive decreases within the 5-9 and 10-14 age groups (81.0% and 74.7% respectively). A similar, significant pattern in survival by age group was found for children with lymphoid leukaemia, but the differences were less pronounced for the diagnostic subgroup of acute myeloid leukaemias (see Appendix Table A.4b, page 45).

**Box 3.1d: Five-year relative survival for childhood leukaemias by age group at diagnosis, Australia, 1995-2004<sup>a</sup>**

Age group at diagnosis	Number of cases <sup>b</sup>	Five-year relative survival (95% CI) <sup>c</sup>
< 1 year	118	53.6 (44.1-62.3)
1-4 years	951	86.2 (83.7-88.3)
5-9 years	569	81.0 (77.4-84.1)
10-14 years	398	74.7 (69.9-78.9)


*p* < 0.001

Notes: a. Cohort includes children diagnosed during 1995-2004 with follow-up to 31 Dec 2006.  
 b. The initial number of eligible cases in the cohort.  
 c. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).

Age group at diagnosis	Relative survival (%)
< 1	53.6
1-4	86.2
5-9	81.0
10-14	74.7

Survival by year of diagnosis

Survival for childhood leukaemia has improved significantly in recent years (Box 3.1e). Children who were diagnosed with leukaemia during 1983-1994 had a 5-year relative survival rate of 69.1% compared to 80.6% during 1995-2004. Improvements in survival were recorded for both lymphoid leukaemias (from 75.5% to 85.3% between 1983-1994 and 1995-2004) and acute myeloid leukaemias (from 44.1% to 62.3% - see Appendix Table A.4d, page 47).



International comparisons

Of the selected countries for which estimates were available (Box 3.1f), 5-year survival for children with leukaemia ranged from 78% in France to 83% in Great Britain, compared to 81% in Australia.

**Box 3.1f: Five-year survival for childhood leukaemias in selected countries<sup>a</sup>**

Country	Years	Number of cases	Method	5-year survival (%) (95% CI) <sup>b,c</sup>
Australia	1995-2004	2,036	Relative survival – cohort method	81 (79-82)
France <sup>13</sup>	1995-1999	567	Observed survival – cohort method	78 (75-82)
Great Britain <sup>14</sup>	2001-2005	2,429	Observed survival – cohort method	83 (81-85)
United States <sup>15</sup>	1999-2006	6,041	Relative survival – cohort method	82 (81-83)

Notes: a. International comparisons should be treated with due caution – see Appendix A.2.3, page 42.  
 b. 95% CI = 95% confidence interval.  
 c. Survival estimates have been rounded to the nearest integer.

### 3.2 Lymphomas and reticuloendothelial neoplasms

#### Background

Lymphomas are also cancers of the lymphoid subgroup of white blood cells, and therefore they have some similarities to lymphoid leukaemias. However, the abnormal white blood cells in lymphomas are principally found in lymph glands, with only occasional bone marrow involvement. Lymph glands are a network of clusters of immune cells which intercept and coordinate the response to infections. These glands, which include the tonsils and adenoids, are found in the neck, armpits, groin and within the chest and abdomen.


There are two main types of lymphoma, depending on the lymphoid cells involved – Hodgkin lymphomas<sup>18</sup> and non-Hodgkin lymphomas<sup>19,20</sup> (which includes the subgroup of Burkitt lymphomas). During 1995-2004, Hodgkin lymphomas accounted for 39.5% of all childhood lymphomas diagnosed within Australia, while 38.9% of cases were non-Hodgkin lymphomas (excluding Burkitt lymphomas) and a further 19.6% were classified as Burkitt lymphomas.

The type of lymphoma determines treatment and prognosis. Hodgkin lymphomas tend to be relatively slow-growing, and cases present with painless lumps at sites where lymph glands are located. Some children with Hodgkin lymphoma also develop fevers and night sweats or experience unexplained weight loss. In contrast, non-Hodgkin lymphomas tend to progress much more rapidly. Children with non-Hodgkin lymphoma usually present as very unwell, with swelling in the abdomen or chest causing obstruction to major organs, such as the bowel or trachea (windpipe).<sup>7,9</sup>

#### Survival by time since diagnosis

The relative rate of survival among children diagnosed with lymphoma decreased slightly from 93.3% 1 year after diagnosis to 89.6% after 5 years, with 10-year relative survival estimated at 87.7% (Box 3.2a).


**Box 3.2a: Relative survival by time since diagnosis for childhood lymphomas (n=607)<sup>a</sup>, Australia, 1995-2004<sup>b</sup>**



#### Survival by diagnostic subgroup

There were significant differences in survival among the main diagnostic subgroups for lymphoma (Box 3.2b). Five-year relative survival rates varied from 82.6% for non-Hodgkin lymphomas (excluding Burkitt lymphoma) to 90.1% for Burkitt lymphomas and 97.1% for Hodgkin lymphomas.


**Box 3.2b: Five-year relative survival for childhood lymphomas by diagnostic subgroup, Australia, 1995-2004<sup>a</sup>**



Survival by sex

The 5-year relative survival rate for childhood lymphoma was similar for boys and girls (89.8% and 89.1% respectively, see Box 3.2c). There were also no significant differences in survival by sex within any of the diagnostic subgroups for lymphoma (see Appendix Table A.4a, page 44).


**Box 3.2c: Five-year relative survival for childhood lymphomas by sex, Australia, 1995-2004<sup>a</sup>**



Survival by age group at diagnosis

No significant differences were found in relative survival by age at diagnosis for children with lymphoma, despite 5-year survival being somewhat higher within the 10-14 age group (91.9%) compared to children who were diagnosed when they were younger (85.4% in the 0-4 age group – see Box 3.2d). Further analysis by diagnostic subgroup revealed that there were no significant differences in survival by age (see Appendix Table A.4b, page 45).


**Box 3.2d: Five-year relative survival for childhood lymphomas by age group at diagnosis, Australia, 1995-2004<sup>a</sup>**



Survival by tumour stage

Survival for childhood lymphoma varied significantly by stage at diagnosis, with 5-year relative survival rates higher for stage I and II tumours (97.0% and 96.0%) and lower for stage III and IV tumours (83.8% and 85.0% - Box 3.2e). A similar pattern was recorded for each of the diagnostic subgroups, although the difference in survival by tumour stage was only statistically significant for Hodgkin lymphomas (Appendix Table A.4c, page 46).


**Box 3.2e: Five-year relative survival for childhood lymphomas by tumour stage<sup>a</sup>, Australia, 1995-2004<sup>b</sup>**



Survival by year of diagnosis

Five-year relative survival for childhood lymphoma improved significantly over time (Box 3.2f), increasing from 80.8% during 1983-1994 to 89.6% during 1995-2004. In terms of the diagnostic subgroups, children with Burkitt lymphoma recorded a statistically significant improvement over the two time periods, with 5-year relative survival increasing from 73.5% to 90.1% (Appendix Table A.4d, page 47).

**Box 3.2f: Five-year relative survival for childhood lymphomas by year of diagnosis, Australia, 1983-2004<sup>a</sup>**



International comparisons

Survival for children with lymphoma was quite consistent (between 88% to 90% after 5 years) in each of the countries for which recent estimates were available (Box 3.2g).

**Box 3.2g: Five-year survival for childhood lymphomas in selected countries<sup>a</sup>**

Country	Years	Number of cases	Method	5-year survival (%) (95% CI) <sup>b,c</sup>
Australia	1995-2004	607	Relative survival – cohort method	90 (87-92)
France <sup>13</sup>	1995-1999	226	Observed survival – cohort method	90 (86-94)
Great Britain <sup>14</sup>	2001-2005	783	Observed survival – cohort method	88 (86-91)
United States <sup>15</sup>	1999-2006	1,783	Relative survival – cohort method	88 (87-90)

Notes: a. International comparisons should be treated with due caution – see Appendix A.2.3, page 42.  
 b. 95% CI = 95% confidence interval.  
 c. Survival estimates have been rounded to the nearest integer.

### 3.3 Central nervous system and miscellaneous intracranial and intraspinal neoplasms

#### Background

The central nervous system (CNS) consists of the brain and the spinal cord, which starts at the base of the brain and extends about half way down the spine. Tumours of the CNS vary widely in terms of pathologic appearance, behaviour and prognosis. They can occur anywhere in the CNS but are most common in the brain, especially among children.<sup>23</sup>


Astrocytomas form the most common diagnostic subgroup and were responsible for 47.7% of all childhood tumours of the CNS diagnosed in Australia during 1995-2004, followed by intracranial and intraspinal embryonal tumours (18.7%), other gliomas (11.7%) and ependymomas and choroid plexus tumours (9.2%). The remaining 12.8% were other specified and unspecified intracranial and intraspinal neoplasms.

Presenting features are determined mainly by the location of the tumour. Many brain tumours result in an increase of pressure within the head. In turn, this may cause headaches, vomiting and sleepiness. Other local effects may include abnormal eye movements, loss of coordination, seizures, weakness in the limbs or difficulties with swallowing.<sup>7,9,24</sup>

Both malignant and non-malignant childhood tumours of the central nervous system may have similar symptoms and outcomes, depending on characteristics such as their histology and grade. Therefore, they have been combined within the same diagnostic group for this report, in accordance with the ICCC-3 classification.<sup>10</sup> Of the 1,406 eligible cases included in the cohort, 859 children (61.1%) had a malignant tumour, while the remaining 547 (38.9%) had tumours that were either benign or of uncertain behaviour.

#### Survival by time since diagnosis

Relative survival for children diagnosed with tumours of the CNS was 82.8% after 1 year, 70.8% after 5 years and 67.7% after 10 years (Box 3.3a).



#### Survival by diagnostic subgroup


Five-year relative survival was highest for the combined diagnostic subgroups of other intracranial and intraspinal neoplasms (92.0%), followed by astrocytomas (77.9%) and ependymomas and choroid plexus tumours (68.6%), while survival was lowest for children with intracranial and intraspinal embryonal tumours (50.5%) and other gliomas (53.8% - see Box 3.3b).

**Box 3.3b: Five-year relative survival for childhood tumours of the central nervous system by diagnostic subgroup, Australia, 1995-2004<sup>a</sup>**

Diagnostic subgroup <sup>b</sup>	Number of cases <sup>c</sup>	Five-year relative survival (95% CI) <sup>d</sup>
EPCPT <sup>e</sup>	129	68.6 (59.6-76.0)
AST	670	77.9 (74.5-80.9)
IJET	263	50.5 (44.2-56.5)
OG	164	53.8 (45.8-61.2)
OIIN <sup>f</sup>	180	92.0 (86.8-95.2)

*p* < 0.001

Notes: a. Cohort includes children diagnosed during 1995-2004 with follow-up to 31 Dec 2006.  
 b. EPCPT = ependymomas and choroid plexus tumours; AST = astrocytomas; IJET = intracranial/intraspinal embryonal tumours; OG = other gliomas; OIIN = other intracranial & intraspinal neoplasms.  
 c. The initial number of eligible cases in the cohort.  
 d. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).  
 e. 5-year relative survival was 65.3% (108 cases) for ependymomas and 85.8% (21 cases) for choroid plexus tumours.  
 f. "Other intracranial and intraspinal neoplasms" include the diagnostic subgroups other specified intracranial & intraspinal neoplasms and unspecified intracranial & intraspinal neoplasms.



Survival by sex


Rates of survival 5 years after diagnosis for childhood tumours of the CNS were similar for boys and girls (70.9% and 70.8% respectively – see Box 3.3c). No significant differences in survival by sex were found within any of the diagnostic subgroups for tumours of the CNS (Appendix Table A.4a, page 44).

**Box 3.3c: Five-year relative survival for childhood tumours of the central nervous system by sex, Australia, 1995-2004<sup>a</sup>**

Sex	Number of cases <sup>b</sup>	Five-year relative survival (95% CI) <sup>c</sup>
Boys	748	70.9 (67.5-74.0)
Girls	658	70.8 (67.0-74.1)

*p* = 0.999


Notes: a. Cohort includes children diagnosed during 1995-2004 with follow-up to 31 Dec 2006.  
 b. The initial number of eligible cases in the cohort.  
 c. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).



Survival by age group at diagnosis

There was a clear trend in survival for childhood tumours of the CNS by age at diagnosis (Box 3.3d). Five-year relative survival increased from 46.5% for children under 1 year old up to 77.8% within the 10-14 age group. The diagnostic subgroups of ependymomas and choroid plexus tumours and intracranial and intraspinal embryonal tumours also exhibited significant differences in survival by age group (see Appendix Table A.4b, page 45). For example, 5-year relative survival for intracranial and intraspinal embryonal tumours ranged from 2.5% among infants (< 1 year old at diagnosis) to 66.2% among children in the 5-9 age group.


**Box 3.3d: Five-year relative survival for childhood tumours of the central nervous system by age group at diagnosis, Australia, 1995-2004<sup>a</sup>**



Survival by year of diagnosis

There was only a small, non-significant increase in 5-year relative survival between 1983-1994 (67.7%) and 1995-2004 (70.8%) for children with tumours of the CNS (Box 3.3e). However, a large improvement was recorded within the diagnostic subgroup of other intracranial and intraspinal tumours, with 5-year relative survival increasing from 80.0% to 92.0% between these two time periods (see Appendix Table A.4d, page 47).

**Box 3.3e: Five-year relative survival for childhood tumours of the central nervous system by year of diagnosis, Australia, 1983-2004<sup>a</sup>**



International comparisons

Five-year survival for childhood tumours of the CNS was similar in Australia to both Great Britain and the United States (each 71%) but somewhat higher than for France (65% - see Box 3.3f).

**Box 3.3f: Five-year survival for childhood tumours of the central nervous system in selected countries<sup>a</sup>**

Country	Years	Number of cases	Method	5-year survival (%) (95% CI) <sup>b,c</sup>
Australia	1995-2004	1,406	Relative survival – cohort method	71 (68-73)
France <sup>13</sup>	1995-1999	402	Observed survival – cohort method	65 (61-70)
Great Britain <sup>14</sup>	2001-2005	1,930	Observed survival – cohort method	71 (69-73)
United States <sup>15</sup>	1999-2006	3,799	Relative survival – cohort method	71 (70-73)

Notes: a. International comparisons should be treated with due caution – see Appendix A.2.3, page 42.  
 b. 95% CI = 95% confidence interval.  
 c. Survival estimates have been rounded to the nearest integer.

### 3.4 Neuroblastoma and other peripheral nervous cell tumours

#### Background

Neuroblastoma is a cancer of specialised nerve cells (neural crest cells) which form the sympathetic nervous system. This system controls automatic body functions, such as blood pressure regulation, and runs along the length of the spine from the neck to the pelvis.


Tumours can develop anywhere along the sympathetic nervous system, but most commonly originate in the adrenal glands in the abdomen. Less common sites include the chest, neck or pelvis. Neuroblastoma often spreads to other parts of the body, such as the bone marrow, bones, liver or skin. However, tumours can also spontaneously regress in some cases, particularly among infants.<sup>9,25</sup>

Symptoms of neuroblastoma depend on the site and size of the tumour. There may be a palpable mass in the abdomen, respiratory problems, or bladder or bowel dysfunction. Older children with widespread disease commonly experience skeletal pain, fever, anaemia or general failure to thrive.<sup>7,9,25</sup>

#### Survival by time since diagnosis

One-year relative survival for children with neuroblastoma was 86.7%. Survival rates continued to decrease further to 68.4% after 5 years, but then stabilised, with 10-year relative survival estimated at 66.2% (Box 3.4a).

**Box 3.4a: Relative survival by time since diagnosis for childhood neuroblastoma (n=367)<sup>a</sup>, Australia, 1995-2004<sup>b</sup>**



#### Survival by diagnostic subgroup

Nearly all cases (98.1%) are in the diagnostic subgroup of neuroblastoma and ganglioneuroblastoma, for which 5-year relative survival was 67.8% (95% confidence interval = 62.6%-72.4%). Separate survival estimates for the subgroup neuroblastoma and ganglioneuroblastoma by sex, age group at diagnosis, tumour stage and year of diagnosis can be found in the Appendix (see Tables A.4a, A.4b, A.4c and A.4d, pages 44-47).


#### Survival by sex

Girls had slightly higher relative survival rates for childhood neuroblastoma compared to boys 5 years after diagnosis (69.7% and 67.3% respectively), but this difference was not statistically significant (Box 3.4b).

**Box 3.4b: Five-year relative survival for childhood neuroblastoma by sex, Australia, 1995-2004<sup>a</sup>**

Sex	Number of cases <sup>b</sup>	Five-year relative survival (95% CI) <sup>c</sup>
Boys	196	67.3 (60.1-73.4)
Girls	171	69.7 (62.0-76.2)
<i>p</i> = 0.590		

Notes: a. Cohort includes children diagnosed during 1995-2004 with follow-up to 31 Dec 2006.  
 b. The initial number of eligible cases in the cohort.  
 c. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).




Survival by age group at diagnosis

Survival for neuroblastoma was significantly higher for infants compared to other children, with 5-year relative survival of 84.6% within the under 1 age group, 57.1% for children aged 1-4 years and 56.4% for children aged 5-14 years (Box 3.4c).

**Box 3.4c: Five-year relative survival for childhood neuroblastoma by age group at diagnosis, Australia, 1995-2004<sup>a</sup>**

Age group at diagnosis <sup>b</sup>	Number of cases <sup>c</sup>	Five-year relative survival (95% CI) <sup>d</sup>
< 1 year	153	84.6 (77.7-89.6)
1-4 years	174	57.1 (49.1-64.2)
5-14 years	40	56.4 (39.4-70.4)
<i>p</i> < 0.001		

Notes: a. Cohort includes children diagnosed during 1995-2004 with follow-up to 31 Dec 2006.  
 b. Age groups "5-9 years" and "10-14 years" have been combined due to the small number of cases in these age groups.  
 c. The initial number of eligible cases in the cohort.  
 d. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).




Survival by tumour stage

A clear gradient was observed in survival from childhood neuroblastoma by stage at diagnosis (Box 3.4d). Relative survival rates were significantly higher for stage I and II tumours (95.6% and 90.9% respectively after 5 years) but decreased sharply for stage III (73.3%) and IV tumours (49.8%).

**Box 3.4d: Five-year relative survival for childhood neuroblastoma by tumour stage<sup>a</sup>, Australia, 1995-2004<sup>b</sup>**

Tumour stage <sup>a</sup>	Number of cases <sup>c,b</sup>	Five-year relative survival (95% CI) <sup>e</sup>
Stage I	68	95.6 (86.5-98.8)
Stage II	44	90.9 (77.0-96.8)
Stage III	46	73.3 (57.4-84.1)
Stage IV	188	49.8 (42.3-56.9)
<i>p</i> < 0.001		


Notes: a. Staged using the International Neuroblastoma Staging System.<sup>26</sup>  
 b. Cohort includes children diagnosed during 1995-2004 with follow-up to 31 Dec 2006.  
 c. The initial number of eligible cases in the cohort.  
 d. Stage was unknown for 21 cases (5.7%).  
 e. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).



Survival by year of diagnosis

A highly significant improvement in survival for children with neuroblastoma was observed between 1983-1994 and 1995-2004, with 5-year relative survival increasing from 52.9% to 68.4% over this period (Box 3.4e).

**Box 3.4e: Five-year relative survival for childhood neuroblastoma by year of diagnosis, Australia, 1983-2004<sup>a</sup>**



International comparisons

Five-year survival for children with neuroblastoma varied from 64% in Great Britain to 73% in both the United States and France, compared to 68% in Australia (Box 3.4f).

**Box 3.4f: Five-year survival for childhood neuroblastoma in selected countries<sup>a</sup>**

Country	Years	Number of cases	Method	5-year survival (%) (95% CI) <sup>b,c</sup>
Australia	1995-2004	367	Relative survival – cohort method	68 (63-73)
France <sup>13</sup>	1995-1999	145	Observed survival – cohort method	73 (66-80)
Great Britain <sup>14</sup>	2001-2005	473	Observed survival – cohort method	64 (59-68)
United States <sup>15</sup>	1999-2006	1,222	Relative survival – cohort method	73 (70-75)

Notes: a. International comparisons should be treated with due caution – see Appendix A.2.3, page 42.  
 b. 95% CI = 95% confidence interval.  
 c. Survival estimates have been rounded to the nearest integer.

### 3.5 Retinoblastoma


#### Background

Retinoblastoma is a cancer that forms in the retina, the light-sensitive tissue at the back of the eye. It almost always develops before the age of five.<sup>27</sup> Tumours may occur in one eye (known as unilateral retinoblastoma) or both eyes (bilateral retinoblastoma).<sup>9,11</sup> Symptoms generally include squinting or eye swelling and redness, but in many children the first sign noted is a visible whiteness of the pupil.<sup>7,9,27,28</sup>

All retinoblastoma is due to a genetic error in the retinal tissue.<sup>28</sup> The error may occur only in the retina (sporadic retinoblastoma) or may be present in all cells in the body (hereditary retinoblastoma). If the genetic error is just in the retina of one eye, only that eye will be affected. However, if it is hereditary, retinoblastoma may develop in either one or both eyes. Children with hereditary retinoblastoma are also at risk of developing other cancers elsewhere in the body, and may pass the genetic error on to their children. Genetic testing can be carried out to determine whether a child has sporadic or hereditary retinoblastoma.

#### Survival by time since diagnosis

The survival of children with retinoblastoma is similar to children in the general population, with relative survival remaining around 99% up to 10 years after diagnosis (Box 3.5a).




#### Survival by diagnostic subgroup

No diagnostic subgroups are defined for retinoblastoma.<sup>10</sup>

#### Survival by sex

There were no deaths within 5 years of diagnosis (i.e. 100% survival) among girls with retinoblastoma in Australia during 1995-2004, while 5-year relative survival was also very high among boys (98.3% - see Box 3.5b).



Survival by age group at diagnosis

Infants (under 1 year of age) diagnosed with retinoblastoma during 1995-2004 had 100% survival within 5 years of diagnosis compared to 97.7% for children aged 1-4 years (Box 3.5c). There were an insufficient number of cases to calculate survival for children aged 5 years and over.

**Box 3.5c: Five-year relative survival for childhood retinoblastoma by age group at diagnosis, Australia, 1995-2004<sup>a</sup>**

Age group at diagnosis <sup>b</sup>	Number of cases <sup>c</sup>	Five-year relative survival (95% CI) <sup>d,e</sup>
< 1 year	69	100.0 n.a.
1-4 years	84	97.7 (90.9-99.5)

Notes: a. Cohort includes children diagnosed during 1995-2004 with follow-up to 31 Dec 2006.

b. Survival estimates could not be calculated within the 5-9 and 10-14 age groups due to the small number of cases diagnosed.

c. The initial number of eligible cases in the cohort.

d. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).

e. n.a. = not applicable. Confidence interval (and corresponding p-value) could not be calculated because no deaths were recorded.

Age group at diagnosis	Relative survival (%)
< 1	100.0
1-4	97.7 (90.9-99.5)

Survival by year of diagnosis

Five-year relative survival for retinoblastoma increased from 95.8% for children diagnosed during 1983-1994 to 99.1% for children diagnosed during 1995-2004, although the difference was not statistically significant (Box 3.5d).

**Box 3.5d: Five-year relative survival for childhood retinoblastoma by year of diagnosis, Australia, 1983-2004<sup>a</sup>**

Year of diagnosis	Number of cases <sup>b</sup>	Five-year relative survival (95% CI) <sup>c</sup>
1983-1994	172	95.8 (91.3-98.1)
1995-2004	159	99.1 (95.4-100.0)

*p* = 0.088

Notes: a. Cohorts include children diagnosed during 1983-1994 and 1995-2004 with follow-up to 31 Dec 2006.

b. The initial number of eligible cases in the cohort.

c. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).

Year of diagnosis	Relative survival (%)
1983-1994	95.8 (91.3-98.1)
1995-2004	99.1 (95.4-100.0)

International comparisons

Survival for children with retinoblastoma was consistently high (98% or better after 5 years) in each of the countries for which recent estimates were available (Box 3.5e).

**Box 3.5e: Five-year survival for childhood retinoblastoma in selected countries<sup>a</sup>**

Country	Years	Number of cases	Method	5-year survival (%) (95% CI) <sup>b,c</sup>
Australia	1995-2004	159	Relative survival – cohort method	99 (95-100)
France <sup>13</sup>	1995-1999	53	Observed survival – cohort method	100 n.a.
Great Britain <sup>14</sup>	2001-2005	205	Observed survival – cohort method	99 (96-100)
United States <sup>15</sup>	1999-2006	523	Relative survival – cohort method	98 (95-99)

Abbreviation: n.a. = not applicable (confidence interval could not be calculated because no deaths were recorded).  
 Notes: a. International comparisons should be treated with due caution – see Appendix A.2.3, page 42.  
 b. 95% CI = 95% confidence interval.  
 c. Survival estimates have been rounded to the nearest integer.

### 3.6 Renal tumours


#### Background

Renal tumours in children often originate from abnormalities during development of the kidneys prior to birth. They tend to grow rapidly and about three quarters of all cases are diagnosed before the age of five. Children with renal tumours usually have cancer in one kidney, but occasionally tumours can develop in both kidneys.<sup>9,29</sup>

The most common symptom is a lump in the abdomen in an otherwise well child. Some children also have abdominal pain, blood in the urine, hypertension (high blood pressure) or fever.<sup>7,9,29,30</sup>

#### Survival by time since diagnosis

Relative survival for children with renal tumours decreased from 96.1% in the first year following diagnosis to 89.2% after 5 years, but then remained quite stable, with 10-year relative survival estimated at 88.4% (Box 3.6a).



#### Survival by diagnostic subgroup

Nephroblastoma (also known as Wilms’ tumour) is by far the most frequent type of renal tumour occurring among children.<sup>30</sup> Almost all (97.0%) childhood renal tumours diagnosed in Australia during 1995-2004 were in the subgroup nephroblastoma and other nonepithelial renal tumours, with a corresponding 5-year relative survival rate of 88.9% (95% confidence interval = 84.8%-92.0%). Separate survival estimates for nephroblastoma and other nonepithelial renal tumours by sex, age group at diagnosis, tumour stage and year of diagnosis can be found in the Appendix (see Tables A.4a, A.4b, A.4c and A.4d, pages 44-47).


#### Survival by sex

Girls appeared to have somewhat higher survival rates for childhood renal tumours compared to boys (5-year relative survival of 92.5% and 85.4% respectively), but the difference by sex was not statistically significant (Box 3.6b).

**Box 3.6b: Five-year relative survival for childhood renal tumours by sex, Australia, 1995–2004<sup>a</sup>**

Sex	Number of cases <sup>b</sup>	Five-year relative survival (95% CI) <sup>c</sup>
Boys	153	85.4 (78.5–90.2)
Girls	175	92.5 (87.4–95.6)
<i>p</i> = 0.068		

Notes: a. Cohort includes children diagnosed during 1995–2004 with follow-up to 31 Dec 2006.  
 b. The initial number of eligible cases in the cohort.  
 c. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).




Survival by age group at diagnosis

Five-year relative survival for renal tumours was considerably lower in the under 1 age group (77.7%) than for children aged 1–4 years (92.1%). However, the differences in survival by age group were not statistically significant overall (Box 3.6c).

**Box 3.6c: Five-year relative survival for childhood renal tumours by age group at diagnosis, Australia, 1995–2004<sup>a</sup>**

Age group at diagnosis <sup>b</sup>	Number of cases <sup>c</sup>	Five-year relative survival (95% CI) <sup>d</sup>
< 1 year	40	77.7 (60.7–88.1)
1–4 years	206	92.1 (87.4–95.1)
5–14 years	82	87.6 (78.2–93.2)
<i>p</i> = 0.078		

Notes: a. Cohort includes children diagnosed during 1995–2004 with follow-up to 31 Dec 2006.  
 b. Age groups “5–9 years” and “10–14 years” have been combined due to the small number of cases in these age groups.  
 c. The initial number of eligible cases in the cohort.  
 d. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).




Survival by tumour stage

Significant variation was recorded in survival for childhood renal tumours by stage at diagnosis (Box 3.6d). Five-year relative survival rates varied from 97.3% for stage I tumours to 74.0% for stage IV tumours.

**Box 3.6d: Five-year relative survival for childhood renal tumours by tumour stage<sup>a</sup>, Australia, 1995–2004<sup>b</sup>**


Tumour stage <sup>a</sup>	Number of cases <sup>c,d</sup>	Five-year relative survival (95% CI) <sup>e</sup>
Stage I	70	97.3 (89.0–99.5)
Stage II	76	92.7 (83.1–97.0)
Stage III	78	92.4 (83.7–96.6)
Stage IV	70	74.0 (61.9–82.8)
<i>p</i> < 0.001		

Notes: a. Staged using the Third National Wilms’ Tumor Study.<sup>31</sup>  
 a. Cohort includes children diagnosed during 1995–2004 with follow-up to 31 Dec 2006.  
 b. The initial number of eligible cases in the cohort.  
 c. Stage was unknown for 34 cases (10.4%).  
 d. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).



Survival by year of diagnosis

There was no significant improvement in survival for children diagnosed with renal tumours during 1983-1994 compared to 1995-2004, with 5-year relative survival estimates of 86.9% and 89.2% respectively (Box 3.6e).



International comparisons

Of the countries for which recent estimates were available, 5-year survival following diagnosis of a renal tumour during childhood varied from 84% in Great Britain to 89% in both Australia and France (Box 3.6f).

**Box 3.6f: Five-year survival for childhood renal tumours in selected countries<sup>a</sup>**

Country	Years	Number of cases	Method	5-year survival (%) (95% CI) <sup>b,c</sup>
Australia	1995-2004	328	Relative survival – cohort method	89 (85-92)
France <sup>13</sup>	1995-1999	125	Observed survival – cohort method	89 (83-94)
Great Britain <sup>14</sup>	2001-2005	444	Observed survival – cohort method	84 (81-88)
United States <sup>15</sup>	1999-2006	938	Relative survival – cohort method	88 (86-90)

Notes: a. International comparisons should be treated with due caution – see Appendix A.2.3, page 42.  
 b. 95% CI = 95% confidence interval.  
 c. Survival estimates have been rounded to the nearest integer.

### 3.7 Hepatic tumours

#### Background


Hepatic tumours are cancers of the liver. It is the least common diagnostic group, constituting only 1.5% of all childhood cancers diagnosed in Australia during 1995-2004. The two main subgroups are hepatoblastoma (83.9%) and hepatic carcinomas (16.1%). Hepatoblastoma usually occur in younger children (under four years of age), while hepatic carcinomas primarily affect children over the age of ten.<sup>7,32,33</sup>

Children with hepatic tumours typically have a painless mass in their abdomen, although some experience abdominal pain, constipation, weight loss or nausea,<sup>32</sup> particularly if the tumour is more advanced.<sup>7</sup>

#### Survival by time since diagnosis

Most of the mortality associated with childhood hepatic tumours occurred in the first 2 to 3 years following diagnosis (Box 3.7a). Relative survival was 86.3% by the end of the first year before a further decrease to 77.3% after 5 years, but from then on the survival rate remained stable.

**Box 3.7a: Relative survival by time since diagnosis for childhood hepatic tumours (n=93)<sup>a</sup>, Australia, 1995-2004<sup>b</sup>**




#### Survival by diagnostic subgroup

Five-year relative survival was 87.1% (95% confidence interval = 77.1%-93.1%) for children diagnosed with hepatoblastoma. There were an insufficient number of cases to calculate separate survival estimates for hepatic carcinomas.

#### Survival by sex


Survival for girls with hepatic tumours appeared to be higher than survival for boys, estimated at 85.4% and 72.6% respectively after 5 years (Box 3.7b). Similar variation was observed for the diagnostic subgroup of hepatoblastoma, with 5-year relative survival of 96.9% for girls compared to 81.5% for boys (Appendix Table A.4a, page 44). However, due to the small number of cases involved, neither of these differences in survival by sex were statistically significant.

**Box 3.7b: Five-year relative survival for childhood hepatic tumours by sex, Australia, 1995-2004<sup>a</sup>**




Survival by age group at diagnosis

A significant decrease in survival was observed for childhood hepatic tumours as age at diagnosis increased. Five-year relative survival was 91.6% for children aged under 1 compared to 83.0% for those in the 1-4 age group and 40.4% for children aged 5-14 (Box 3.7c). This outcome is influenced by differences in the age distribution for the diagnostic subgroups. When the analysis was limited to children under 5 years old who were diagnosed with hepatoblastoma, there was no difference between the under 1 and 1-4 age groups, with 5-year relative survival of 91.6% and 91.8% respectively (see Appendix Table A.4b, page 45).



Survival by year of diagnosis

Similar results were obtained for children diagnosed with hepatic tumours during 1983-1994 and 1995-2004, with 5-year relative survival estimated at 77.0% and 77.3% respectively (Box 3.7d). Despite a small increase, there was no significant improvement over time for children with hepatoblastoma, for whom 5-year relative survival was 82.6% during 1983-1994 compared to 87.1% during 1995-2004 (Appendix Table A.4d, page 47).



International comparisons

Five-year survival for children with hepatic tumours in Australia (77%) compared favourably with other developed countries for which estimates were available (Box 3.7e).

**Box 3.7e: Five-year survival for childhood hepatic tumours in selected countries<sup>a</sup>**

Country	Years	Number of cases	Method	5-year survival (%) (95% CI) <sup>b,c</sup>
Australia	1995-2004	93	Relative survival – cohort method	77 (67-85)
France <sup>13</sup>	1995-1999	19	Observed survival – cohort method	74 (54-94)
Great Britain <sup>14</sup>	2001-2005	90	Observed survival – cohort method	66 (55-74)
United States <sup>15</sup>	1999-2006	308	Relative survival – cohort method	66 (60-72)

Notes: a. International comparisons should be treated with due caution – see Appendix A.2.3, page 42.  
 b. 95% CI = 95% confidence interval.  
 c. Survival estimates have been rounded to the nearest integer.

### 3.8 Malignant bone tumours

#### Background

Childhood malignant bone tumours can occur at any age but are usually diagnosed around the age of puberty. The two main subgroups are Ewing tumours and related bone sarcomas and osteosarcomas, which occur in almost equal numbers (responsible for 47.1% and 46.4% of all childhood malignant bone tumours diagnosed in Australia during 1995-2004, respectively).


Osteosarcomas often originate at the ends of the long bones in the arms and legs (particularly around the knee) where new bone tissue forms as a child grows. Ewing sarcomas are more likely to develop at a range of sites, including the legs, pelvis, arms, ribs or spine.<sup>7,9,34</sup>

The most common symptom of malignant bone tumours is localised pain at the tumour site that may persist at night. This can be accompanied by tenderness, swelling and fever in more advanced cases.<sup>7,9</sup>

#### Survival by time since diagnosis

By the end of the first year after diagnosis, relative survival for childhood malignant bone tumours was 93.3%. Survival continued to decrease steadily to 69.5% after 5 years before a further small decline to 65.6% after 10 years (Box 3.8a).

**Box 3.8a: Relative survival by time since diagnosis for childhood malignant bone tumours (n=263)<sup>a</sup>, Australia, 1995-2004<sup>b</sup>**



#### Survival by diagnostic subgroup

Children diagnosed with osteosarcomas had a slightly higher rate of 5-year relative survival compared to those with Ewing tumours, estimated at 70.6% and 67.8% respectively, but the difference in survival between these diagnostic subgroups was not statistically significant (Box 3.8b).

**Box 3.8b: Five-year relative survival for childhood malignant bone tumours by diagnostic subgroup, Australia, 1995-2004<sup>a</sup>**

Diagnostic subgroup <sup>b</sup>	Number of cases <sup>c</sup>	Five-year relative survival (95% CI) <sup>d</sup>
OST	122	70.6 (61.2-78.1)
EWS	124	67.8 (58.0-75.8)

*p* = 0.570

Notes: a. Cohort includes children diagnosed during 1995-2004 with follow-up to 31 Dec 2006.  
 b. OST = osteosarcomas; EWS = Ewing tumours and related bone sarcomas.  
 c. The initial number of eligible cases in the cohort.  
 d. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).

Diagnostic subgroup	Relative survival (%)
OST	70.6
EWS	67.8

Survival by sex

Although 5-year relative survival for childhood malignant bone tumours was slightly higher for girls than boys (71.1% and 68.1% respectively), the difference was not statistically significant (Box 3.8c). There were also no significant differences in survival by sex for either osteosarcomas or Ewing tumours (see Appendix Table A.4a, page 44).

**Box 3.8c: Five-year relative survival for childhood malignant bone tumours by sex, Australia, 1995-2004<sup>a</sup>**

Sex	Number of cases <sup>b</sup>	Five-year relative survival (95% CI) <sup>c</sup>
Boys	135	68.1 (59.0-75.6)
Girls	128	71.1 (61.8-78.6)

*p* = 0.502

Notes: a. Cohort includes children diagnosed during 1995-2004 with follow-up to 31 Dec 2006.  
 b. The initial number of eligible cases in the cohort.  
 c. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).

Sex	Relative survival (%)
Boys	68.1
Girls	71.1

Survival by age group at diagnosis

Five-year relative survival for malignant bone tumours was higher for children aged 5-9 years old at the time of diagnosis (84.5%) compared to those in either the 0-4 or 10-14 age groups (66.0% and 64.9% respectively - see Box 3.8d). Similar patterns were evident for both osteosarcomas and Ewing tumours (Appendix Table A.4b, page 45), but the differences in survival by age group were not statistically significant for either of these diagnostic subgroups.

**Box 3.8d: Five-year relative survival for childhood malignant bone tumours by age group at diagnosis, Australia, 1995-2004<sup>a</sup>**

Age group at diagnosis <sup>b</sup>	Number of cases <sup>c</sup>	Five-year relative survival (95% CI) <sup>d</sup>
0-4 years	27	66.0 (44.0-81.0)
5-9 years	62	84.5 (72.3-91.6)
10-14 years	174	64.9 (56.7-71.9)

*p* = 0.020

Notes: a. Cohort includes children diagnosed during 1995-2004 with follow-up to 31 Dec 2006.  
 b. Age groups “< 1 year” and “1-4 years” have been combined due to the small number of cases in these age groups.  
 c. The initial number of eligible cases in the cohort.  
 d. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).

Age group at diagnosis	Relative survival (%)
0-4	66.0
5-9	84.5
10-14	64.9

Survival by year of diagnosis

A small, non-significant improvement was observed in survival for children with malignant bone tumours between 1983-1994 and 1995-2004, with 5-year relative survival estimates of 66.0% and 69.5% recorded over the two time periods (Box 3.8e). No significant change in survival over time was recorded for the diagnostic subgroups of either osteosarcomas or Ewing tumours (Appendix Table A.4d, page 47).

**Box 3.8e: Five-year relative survival for childhood malignant bone tumours by year of diagnosis, Australia, 1983-2004<sup>a</sup>**

Year of diagnosis	Number of cases <sup>b</sup>	Five-year relative survival (95% CI) <sup>c</sup>
1983-1994	287	66.0 (60.2-71.1)
1995-2004	263	69.5 (63.2-75.0)
<i>p</i> = 0.322		

Notes: a. Cohorts include children diagnosed during 1983-1994 and 1995-2004 with follow-up to 31 Dec 2006.

b. The initial number of eligible cases in the cohort.

c. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).

Year of diagnosis	Relative survival (%)
1983-1994	66.0
1995-2004	69.5

International comparisons

As shown in Box 3.8f, 5-year survival for children with malignant bone tumours varied from 61% in Great Britain to 77% in France, compared to 70% for Australia.

**Box 3.8f: Five-year survival for childhood malignant bone tumours in selected countries<sup>a</sup>**

Country	Years	Number of cases	Method	5-year survival (%) (95% CI) <sup>b,c</sup>
Australia	1995-2004	263	Relative survival – cohort method	70 (63-75)
France <sup>13</sup>	1995-1999	104	Observed survival – cohort method	77 (69-85)
Great Britain <sup>14</sup>	2001-2005	321	Observed survival – cohort method	61 (55-66)
United States <sup>15</sup>	1999-2006	788	Relative survival – cohort method	71 (67-74)

Notes: a. International comparisons should be treated with due caution – see Appendix A.2.3, page 42.  
 b. 95% CI = 95% confidence interval.  
 c. Survival estimates have been rounded to the nearest integer.

### 3.9 Soft tissue and other extraosseous sarcomas

#### Background


Soft tissue sarcomas are a diverse group of cancers that develop in the soft tissues (such as muscles, fat, blood vessels, lymphatic vessels, nerves, ligaments and tendons) which connect, support or surround bones and organs.

The most common subgroup of childhood soft tissue sarcomas is rhabdomyosarcomas, which accounted for almost half (48.0%) of all soft tissue sarcomas diagnosed among Australian children during 1995-2004. These tumours usually occur before ten years of age and typically begin in muscles around the bones, especially in the head, neck and genitourinary tract.<sup>9,35,36</sup> In contrast, other types of soft tissue sarcomas (referred to collectively as non-rhabdomyosarcoma soft tissue sarcomas) tend to occur in the extremities of the body (i.e. arms and legs) and are more common among older children.<sup>35-37</sup>

Children with soft tissue sarcoma may develop a lump at the involved site. Other symptoms tend to be site-specific, such as headaches, sinusitis, persistent ear or nasal discharge or protrusion of the eyeball for head and neck tumours, or abnormal urine flow accompanying genitourinary tumours.<sup>9,35-37</sup>

#### Survival by time since diagnosis

The relative rate of survival among children diagnosed with soft tissue sarcoma gradually decreased from 90.0% 1 year after diagnosis to 70.6% after 5 years, but then remained fairly stable, with 10-year relative survival estimated at 67.2% (Box 3.9a).



#### Survival by diagnostic subgroup

Five-year relative survival was somewhat lower for rhabdomyosarcomas (68.2%) compared to non-rhabdomyosarcoma soft tissue sarcomas (72.5%), but the difference was not statistically significant (Box 3.9b).

**Box 3.9b: Five-year relative survival for childhood soft tissue sarcomas by diagnostic subgroup, Australia, 1995-2004<sup>a</sup>**

Diagnostic subgroup <sup>b</sup>	Number of cases <sup>c</sup>	Five-year relative survival (95% CI) <sup>d</sup>
RMS	160	68.2 (59.9-75.2)
NRSTS <sup>e</sup>	173	72.5 (65.0-78.6)

*p* = 0.272

Notes: a. Cohort includes children diagnosed during 1995-2004 with follow-up to 31 Dec 2006.

b. RMS = rhabdomyosarcomas; NRSTS = non-rhabdomyosarcoma soft tissue sarcomas.

c. The initial number of eligible cases in the cohort.

d. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).

e. NRSTS include the diagnostic subgroups fibrosarcomas and other fibrous neoplasms, Kaposi sarcomas, other specified soft tissue sarcomas and unspecified soft tissue sarcomas.

Diagnostic subgroup	Relative survival (%)
RMS	68.2
NRSTS	72.5

Survival by sex

Girls had slightly higher 5-year relative survival for childhood soft tissue sarcomas compared to boys (72.5% and 69.0% respectively), but this difference was not statistically significant (Box 3.9c). There was also no significant difference in survival by sex for either rhabdomyosarcomas or non-rhabdomyosarcoma soft tissue sarcomas (see Appendix Table A.4a, page 44).

**Box 3.9c: Five-year relative survival for childhood soft tissue sarcomas by sex, Australia, 1995-2004<sup>a</sup>**

Sex	Number of cases <sup>b</sup>	Five-year relative survival (95% CI) <sup>c</sup>
Boys	182	69.0 (61.4-75.5)
Girls	151	72.5 (64.3-79.1)

*p* = 0.392

Notes: a. Cohort includes children diagnosed during 1995-2004 with follow-up to 31 Dec 2006.

b. The initial number of eligible cases in the cohort.

c. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).

Sex	Relative survival (%)
Boys	69.0
Girls	72.5

Survival by age group at diagnosis

No significant differences were found in relative survival by age at diagnosis for children with soft tissue sarcomas, although the estimates of 5-year survival were somewhat higher within the 0-4 (74.6%) and 5-9 (71.5%) age groups compared to children aged 10-14 years old (66.0% – see Box 3.9d). The variation by age was more pronounced within the diagnostic subgroup of rhabdomyosarcomas, with 5-year relative survival ranging from 75.4% for children aged 0-4 years to 43.8% in the 10-14 age group (Appendix Table A.4b, page 45).

**Box 3.9d: Five-year relative survival for childhood soft tissue sarcomas by age group at diagnosis, Australia, 1995-2004<sup>a</sup>**

Age group at diagnosis <sup>b</sup>	Number of cases <sup>c</sup>	Five-year relative survival (95% CI) <sup>d</sup>
0-4 years	123	74.6 (65.6-81.6)
5-9 years	90	71.5 (60.4-80.0)
10-14 years	120	66.0 (56.4-74.0)

*p* = 0.318

Notes: a. Cohort includes children diagnosed during 1995-2004 with follow-up to 31 Dec 2006.

b. Age groups “< 1 year” and “1-4 years” have been combined due to the small number of cases in the < 1 age group.


c. The initial number of eligible cases in the cohort.

d. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).

Age group at diagnosis	Relative survival (%)
0-4	74.6
5-9	71.5
10-14	66.0


Survival by tumour stage

Staging of tumours for childhood soft tissue sarcomas was only available for the diagnostic subgroup of rhabdomyosarcomas. Survival varied significantly by stage (Box 3.9e), with 5-year relative survival rates higher for stage I and II tumours combined (83.0%) compared to stage III and IV tumours combined (53.0%).



Survival by year of diagnosis

Five-year relative survival for childhood soft tissue sarcomas decreased slightly from 73.4% during 1983-1994 to 70.6% during 1995-2004, although the difference was not statistically significant (Box 3.9f). However, when the diagnostic subgroups were analysed separately, a significant decrease was observed for non-rhabdomyosarcoma soft tissue sarcomas, with 5-year relative survival declining from 84.5% to 72.5% over the interval 1983-1994 to 1995-2004 (see Appendix Table A.4d, page 47).



International comparisons

Children with soft tissue sarcomas in Australia had similar 5-year survival compared to children in the United States (71% and 72% respectively - see Box 3.9g).

**Box 3.9g: Five-year survival for childhood soft tissue sarcomas in selected countries<sup>a</sup>**

Country	Years	Number of cases	Method	5-year survival (%) (95% CI) <sup>b,c</sup>
Australia	1995-2004	333	Relative survival – cohort method	71 (65-75)
France <sup>13</sup>	1995-1999	95	Observed survival – cohort method	66 (57-76)
Great Britain <sup>14</sup>	2001-2005	513	Observed survival – cohort method	67 (63-71)
United States <sup>15</sup>	1999-2006	1,285	Relative survival – cohort method	72 (69-75)

Notes: a. International comparisons should be treated with due caution – see Appendix A.2.3, page 42.  
 b. 95% CI = 95% confidence interval.  
 c. Survival estimates have been rounded to the nearest integer.

### 3.10 Germ cell tumours, trophoblastic tumours and neoplasms of gonads

#### Background

Germ cell tumours are comprised of a varied group of cancers that originate from cells that normally develop into gonads (testicles in boys and ovaries in girls). Hence, germ cell tumours usually affect the gonads. However, it is possible for germ cell tumours to occur in other parts of the body, particularly the pelvis, brain or chest.<sup>7,9,39,40</sup>

The most common diagnostic subgroup is malignant gonadal germ cell tumours, accounting for 42.2% of germ cell tumour cases in Australia over the period 1995-2004, followed by and intracranial and intra-gonadal germ cell tumours (28.3%) and malignant extracranial and extragonadal germ cell tumours (27.5%).


Signs and symptoms of germ cell tumours vary by site, and may include swelling in the buttocks, testicular enlargement in boys, an abdominal mass, bladder or bowel obstruction or respiratory problems.<sup>7,9,39,40</sup>

In accordance with the standard international classification for childhood cancers (ICCC-3),<sup>10</sup> non-malignant intracranial and intraspinal germ cell tumours have been included in the data presented for this diagnostic group. Of the 69 cases in that subgroup, 48 children (69.6%) had tumours that were malignant and 21 children (30.4%) had either benign tumours or tumours of uncertain behaviour.

#### Survival by time since diagnosis

The relative rate of survival among children diagnosed with germ cell tumours decreased slightly from 93.1% 1 year after diagnosis to 90.5% after 5 years, with 10-year relative survival estimated at 89.5% (Box 3.10a).

**Box 3.10a: Relative survival by time since diagnosis for childhood germ cell tumours (n=244)<sup>a</sup>, Australia, 1995-2004<sup>b</sup>**



#### Survival by diagnostic subgroup

Children with malignant gonadal germ cell tumours had significantly higher 5-year relative survival (99.2%) compared to those diagnosed with either intracranial & intraspinal germ cell tumours (84.5%) or malignant extracranial & extragonadal germ cell tumours (86.8% - see Box 3.10b).

**Box 3.10b: Five-year relative survival for childhood germ cell tumours by diagnostic subgroup, Australia, 1995-2004<sup>a</sup>**

Diagnostic subgroup <sup>b</sup>	Number of cases <sup>c</sup>	Five-year relative survival (95% CI) <sup>d</sup>
IIGCT	69	84.5 (72.8-91.5)
EEGCT	67	86.8 (76.0-93.0)
GGCT	103	99.2 (93.5-100.0)

*p* < 0.001

Notes: a. Cohort includes children diagnosed during 1995-2004 with follow-up to 31 Dec 2006.  
 b. IIGCT = intracranial & intraspinal germ cell tumours; EEGCT = malignant extracranial & extragonadal germ cell tumours; GGCT = malignant gonadal germ cell tumours.  
 c. The initial number of eligible cases in the cohort.  
 d. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).

Diagnostic subgroup	Relative survival (%)
IIGCT	84.5
EEGCT	86.8
GGCT	99.2

Survival by sex

Survival following a diagnosis of childhood germ cell tumours was slightly higher for boys than for girls, with 5-year relative survival estimated at 92.3% and 88.6% respectively, but the difference was not statistically significant (Box 3.10c). There were also no significant differences in survival by sex for any of the germ cell tumour diagnostic subgroups (see Appendix Table A.4a, page 44).

**Box 3.10c: Five-year relative survival for childhood germ cell tumours by sex, Australia, 1995-2004<sup>a</sup>**

Sex	Number of cases <sup>b</sup>	Five-year relative survival (95% CI) <sup>c</sup>
Boys	126	92.3 (86.0-95.9)
Girls	118	88.6 (81.0-93.3)

*p* = 0.495

Notes: a. Cohort includes children diagnosed during 1995-2004 with follow-up to 31 Dec 2006.  
 b. The initial number of eligible cases in the cohort.  
 c. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).

Sex	Relative survival (%)
Boys	92.3
Girls	88.6

Survival by age group at diagnosis

Only minor variations were observed in survival for childhood germ cell tumours by age at diagnosis, with 5-year relative survival close to 90% within each of the age groups (Box 3.10d). Survival was also similar irrespective of age at diagnosis within each of the diagnostic subgroups for germ cell tumours (Appendix Table A.4b, page 45).

**Box 3.10d: Five-year relative survival for childhood germ cell tumours by age group at diagnosis, Australia, 1995-2004<sup>a</sup>**

Age group at diagnosis	Number of cases <sup>b</sup>	Five-year relative survival (95% CI) <sup>c</sup>
< 1 year	59	90.2 (79.2-95.7)
1-4 years	67	92.6 (83.1-96.9)
5-9 years	32	86.9 (68.7-94.9)
10-14 years	86	90.6 (81.7-95.3)

*p* = 0.914

Notes: a. Cohort includes children diagnosed during 1995-2004 with follow-up to 31 Dec 2006.  
 b. The initial number of eligible cases in the cohort.  
 c. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).

Age group at diagnosis	Relative survival (%)
< 1	90.2
1-4	92.6
5-9	86.9
10-14	90.6

Survival by year of diagnosis

There was some evidence of an improvement in 5-year relative survival between 1983-1994 (84.4%) and 1995-2004 (90.5%) for children with germ cell tumours (Box 3.10e). A corresponding pattern over time was recorded in each of the germ cell tumour diagnostic subgroups (Appendix Table A.4d, page 47). However, none of these increases in survival were statistically significant.

**Box 3.10e: Five-year relative survival for childhood germ cell tumours by year of diagnosis, Australia, 1983-2004<sup>a</sup>**

Year of diagnosis	Number of cases <sup>b</sup>	Five-year relative survival (95% CI) <sup>c</sup>
1983-1994	208	84.4 (78.6-88.7)
1995-2004	244	90.5 (86.0-93.7)
<i>p</i> = 0.081		

Notes: a. Cohorts include children diagnosed during 1983-1994 and 1995-2004 with follow-up to 31 Dec 2006.  
 b. The initial number of eligible cases in the cohort.  
 c. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).

Year of diagnosis	Relative survival (%)
1983-1994	84.4
1995-2004	90.5

International comparisons

Survival for children diagnosed with germ cell tumours in Australia (91% after 5 years) was similar to the outcomes reported for Great Britain (92%) and the United States (89% - see Box 3.10f).

**Box 3.10f: Five-year survival for childhood germ cell tumours in selected countries<sup>a</sup>**

Country	Years	Number of cases	Method	5-year survival (%) (95% CI) <sup>b,c</sup>
Australia	1995-2004	244	Relative survival – cohort method	91 (86-94)
France <sup>13</sup>	1995-1999	62	Observed survival – cohort method	86 (77-94)
Great Britain <sup>14</sup>	2001-2005	245	Observed survival – cohort method	92 (88-95)
United States <sup>15</sup>	1999-2006	700	Relative survival – cohort method	89 (86-91)

Notes: a. International comparisons should be treated with due caution – see Appendix A.2.3, page 42.  
 b. 95% CI = 95% confidence interval.  
 c. Survival estimates have been rounded to the nearest integer.

### 3.11 Other malignant epithelial neoplasms and melanomas

#### Background

*Other malignant epithelial neoplasms:* Epithelial cells form the outer layer of the skin and line the internal cavities of the body. Most glands are also composed of epithelial cells. Tumours that originate in epithelial cells are called carcinomas. Although many of the types of cancers found in adults are classified as carcinomas, they are relatively rare among children, especially within the younger age groups.<sup>9</sup>


Thyroid carcinomas form one of the more common subgroups,<sup>11</sup> accounting for 17.3% of all cases within this diagnostic group in Australia during 1995-2004. Carcinomas of the thyroid are seldom accompanied by symptoms other than a painless mass in the neck.<sup>7</sup>

*Melanomas:* This is a type of skin cancer that originates in melanocytes, the cells which produce the pigment melanin that gives colour to a person’s skin, hair, and eyes. Melanomas constituted over half (54.0%) of all new cases within this diagnostic group during 1995-2004.

Diagnosis of melanoma usually follows the discovery of a suspicious lesion on the skin, particularly when there has been itching, bleeding or a sudden change in size or colour.<sup>7,41,42</sup> The much higher incidence of melanoma in all age groups, including childhood, reported in Australia compared to the rest of the world is likely to be due to the high exposure to ultra-violet (UV) radiation from the sun experienced in most of the country, in combination with a large proportion of the population having skin that is more susceptible to sun damage.<sup>11</sup>

#### Survival by time since diagnosis

The relative rate of survival among children diagnosed with other malignant epithelial neoplasms and melanomas decreased slightly from 96.9% in the first year after diagnosis to 93.0% after 5 years, but then remained fairly stable, with 10-year relative survival estimated at 92.0% (Box 3.11a).



#### Survival by diagnostic subgroup

Five-year relative survival was significantly higher for children with either a thyroid carcinoma (97.9%) or melanoma (97.0%) compared to those diagnosed with other carcinomas (82.2% - see Box 3.11b).

**Box 3.11b: Five-year relative survival for other childhood malignant epithelial neoplasms and melanomas by diagnostic subgroup, Australia, 1995-2004<sup>a</sup>**

Diagnostic subgroup <sup>b</sup>	Number of cases <sup>c</sup>	Five-year relative survival (95% CI) <sup>d</sup>
TC	56	97.9 (85.9-99.8)
MM	175	97.0 (92.8-98.8)
OC <sup>e</sup>	93	82.2 (72.6-88.8)

*p* < 0.001

Notes: a. Cohort includes children diagnosed during 1995-2004 with follow-up to 31 Dec 2006.  
 b. TC = thyroid carcinomas; MM = malignant melanomas; OC = other carcinomas.  
 c. The initial number of eligible cases in the cohort.  
 d. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).  
 e. "Other carcinomas" are a combination of the diagnostic subgroups adrenocortical carcinomas, nasopharyngeal carcinomas, skin carcinomas, and other and unspecified carcinomas.

Survival by sex

Although 5-year relative survival for other childhood malignant epithelial neoplasms and melanomas was slightly higher for girls than boys (94.5% and 91.0% respectively), the difference was not statistically significant (Box 3.11c). No significant differences in survival by sex were found for any of the diagnostic subgroups for other malignant epithelial neoplasms and melanomas (see Appendix Table A.4a, page 44).

**Box 3.11c: Five-year relative survival for other childhood malignant epithelial neoplasms and melanomas by sex, Australia, 1995-2004<sup>a</sup>**

Sex	Number of cases <sup>b</sup>	Five-year relative survival (95% CI) <sup>c</sup>
Boys	141	91.0 (84.5-94.9)
Girls	183	94.5 (90.0-97.1)

*p* = 0.267

Notes: a. Cohort includes children diagnosed during 1995-2004 with follow-up to 31 Dec 2006.  
 b. The initial number of eligible cases in the cohort.  
 c. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).

Survival by age group at diagnosis

There were no significant differences in 5-year relative survival for other malignant epithelial neoplasms and melanomas by age at diagnosis, with results varying from 90.6% among children aged 5-9 years to 93.6% for those in the 10-14 age group (Box 3.11d). Survival estimates by age within the diagnostic subgroups could only be calculated for older children, and are shown in Appendix Table A.4b, page 45.

**Box 3.11d: Five-year relative survival for other childhood malignant epithelial neoplasms and melanomas by age group at diagnosis, Australia, 1995-2004<sup>a</sup>**

Age group at diagnosis <sup>b</sup>	Number of cases <sup>c</sup>	Five-year relative survival (95% CI) <sup>d</sup>
0-4 years	24	91.5 (69.9-98.0)
5-9 years	54	90.6 (79.0-96.0)
10-14 years	246	93.6 (89.5-96.2)

*p* = 0.607

Notes: a. Cohort includes children diagnosed during 1995-2004 with follow-up to 31 Dec 2006.  
 b. Age groups "< 1 year" and "1-4 years" have been combined due to the small number of cases in these age groups.  
 c. The initial number of eligible cases in the cohort.  
 d. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).

Survival by year of diagnosis

There appeared to be a small increase in survival for children with other malignant epithelial neoplasms and melanomas between 1983-1994 and 1995-2004, with 5-year relative survival estimates of 89.6% and 93.0% recorded over the two time periods (Box 3.11e). However, the difference was not statistically significant. Similar, small improvements also occurred within the various diagnostic subgroups for other malignant epithelial neoplasms and melanomas, but again these changes over time were not significant (see Appendix Table A.4d, page 47).

**Box 3.11e: Five-year relative survival for other childhood malignant epithelial neoplasms and melanomas by year of diagnosis, Australia, 1983-2004<sup>a</sup>**

Year of diagnosis	Number of cases <sup>b</sup>	Five-year relative survival (95% CI) <sup>c</sup>
1983-1994	332	89.6 (85.8-92.5)
1995-2004	324	93.0 (89.4-95.4)
<i>p</i> = 0.128		

Notes: a. Cohorts include children diagnosed during 1983-1994 and 1995-2004 with follow-up to 31 Dec 2006.  
 b. The initial number of eligible cases in the cohort.  
 c. 95% CI = 95% confidence interval (shown as vertical black lines on bar graph).

Year of diagnosis	Relative survival (%)
1983-1994	89.6
1995-2004	93.0

International comparisons

Five-year survival for children diagnosed with other malignant epithelial neoplasms and melanomas was as good or better in Australia compared to the other countries for which estimates were available (Box 3.11f). The result for Australia was in part due to the proportionally high incidence of childhood melanoma combined with a particularly high survival rate within this subgroup - survival for melanoma was 97% after 5 years among children in Australia (Box 3.11b), compared to 94% in the United States<sup>15</sup>.

**Box 3.11f: Five-year survival for other childhood malignant epithelial neoplasms and melanomas in selected countries<sup>a,b</sup>**

Country <sup>c</sup>	Years	Number of cases	Method	5-year survival (%) (95% CI) <sup>c,d</sup>
Australia	1995-2004	324	Relative survival – cohort method	93 (90-95)
France <sup>13</sup>	1995-1999	61	Observed survival – cohort method	88 (80-96)
United States <sup>15</sup>	1999-2006	720	Relative survival – cohort method	91 (88-93)

Notes: a. International comparisons should be treated with due caution – see Appendix A.2.3, page 42.  
 b. A survival estimate for this diagnostic group was not published for Great Britain.<sup>14</sup>  
 c. 95% CI = 95% confidence interval.  
 d. Survival estimates have been rounded to the nearest integer.

## Appendix

## A.1 Codes for childhood cancer diagnostic groups

The International Classification of Childhood Cancers, version three (ICCC-3) classifies tumours according to the International Classification of Diseases for Oncology, third edition (ICD-O-3)<sup>43</sup> into 12 main diagnostic groups and 47 subgroups (Table A.1).

Table A.1: International Classification of Childhood Cancer, Third Edition (ICCC-3)

Diagnostic group/subgroup <sup>1</sup>	ICD-O-3 codes <sup>43</sup>	
	Histology	Site
<b>I. Leukaemias, myeloproliferative &amp; myelodysplastic diseases</b>		
a. Lymphoid leukaemias	9820,9823,9826,9827,9831-9837,9940,9948	C000-C809
b. Acute myeloid leukaemias	9840,9861,9866,9867,9870-9874,9891,9895-9897,9910,9920,9931	C000-C809
c. Chronic myeloproliferative diseases	9863,9875,9876,9950,9960-9964	C000-C809
d. Other myeloproliferative diseases	9945,9946,9975,9980,9982-9987,9989	C000-C809
e. Other & unspecified leukaemias	9800,9801,9805,9860,9930	C000-C809
<b>II. Lymphomas &amp; reticuloendothelial tumours</b>		
a. Hodgkin lymphomas	9650-9655,9659,9661-9665,9667	C000-C809
b. Non-Hodgkin lymphomas (excluding Burkitt lymphomas)	9591,9670,9671,9673,9675,9678-9680,9684,9689-9691,9695,9698-9702,9705,9708,9709,9714,9716-9719,9727-9729,9731-9734,9760-9762,9764-9769,9970	C000-C809
c. Burkitt lymphomas	9687	C000-C809
d. Miscellaneous lymphoreticular neoplasms	9740-9742,9750,9754-9758	C000-C809
e. Unspecified lymphomas	9590,9596	C000-C809
<b>III. Central nervous system &amp; intracranial/intraspinal tumours*</b>		
a. Ependymomas and choroid plexus tumours*	9383,9390-9394	C000-C809
b. Astrocytomas*	9380	C723
	9384,9400-9411,9420,9421-9424,9440-9442	C000-C809
c. Intracranial & intraspinal embryonal tumours*	9470-9474,9480,9508	C000-C809
	9501-9504	C700-C729
d. Other gliomas*	9380	C700-C722,C724-C729, C751,C753
	9381,9382,9430,9444,9450,9451,9460	C000-C809
e. Other specified intracranial & intraspinal neoplasms*	8270-8281,8300,9350-9352,9360-9362,9412,9413,9492,9493,9505-9507,9530-9539,9582	C000-C809
f. Unspecified intracranial & intraspinal neoplasms*	8000-8005	C700-C729,C751-C753
<b>IV. Neuroblastomas &amp; other peripheral nervous cell tumours</b>		
a. Neuroblastomas & ganglioneuroblastomas	9490,9500	C000-C809
b. Other peripheral nervous cell tumours	8680-8683,8690-8693,8700,9520-9523	C000-C809
	9501-9504	C000-C699,C739-C768, C809
<b>V. Retinoblastomas</b>		
	9510-9514	C000-C809
<b>VI. Renal tumours</b>		
a. Nephroblastomas & other nonepithelial renal tumours	8959,8960,8964-8967	C000-C809
	8963,9364	C649
b. Renal carcinomas	8010-8041,8050-8075,8082,8120-8122,8130-8141,8143,8155,8190-8201,8210,8211,8221-8231,8240,8241,8244-8246,8260-8263,8290,8310,8320,8323,8401,8430,8440,8480-8490,8504,8510,8550,8560-8576	C649
	8311,8312,8316-8319,8361	C000-C809
c. Unspecified malignant renal tumours	8000-8005	C649

(Continued next page...)

Source: Steliarova-Foucher et al., 2005.<sup>10</sup>

Note: \* Diagnostic group/subgroup includes intracranial and intraspinal tumours of benign or uncertain behaviour.

**Table A.1 (cont.): International Classification of Childhood Cancer, Third Edition (ICCC-3)**

Diagnostic group/subgroup <sup>1</sup>	ICD-O-3 codes <sup>43</sup>	
	Histology	Site
<b>VII. Hepatic tumours</b>		
a. Hepatoblastomas	8970	C000-C809
b. Hepatic carcinomas	8010-8041,8050-8075,8082,8120-8122,8140, 8141,8143,8155,8190-8201,8210,8211,8230, 8231,8240,8241,8244-8246,8260-8264,8310, 8320,8323,8401,8430,8440,8480-8490,8504, 8510,8550,8560-8576 8160-8180	C220,C221 C000-C809
c. Unspecified malignant hepatic tumours	8000-8005	C220,C221
<b>VIII. Malignant bone tumours</b>		
a. Osteosarcomas	9180-9187,9191-9195,9200	C400-C419,C760-C768, C809
b. Chondrosarcomas	9210,9220,9240 9221,9230,9241-9243	C400-C419,C760-C768, C809 C000-C809
c. Ewing's tumours & related bone sarcomas	9260 9363-9365	C400-C419,C760-C768, C809 C400-C419
d. Other specified malignant bone tumours	8810,8811,8823,8830 8812,9250,9261,9262,9270-9275,9280-9282, 9290,9300-9302,9310-9312,9320-9322,9330, 9340-9342,9370-9372	C400-C419 C000-C809
e. Unspecified malignant bone tumours	8000-8005,8800,8801,8803-8805	C400-C419
<b>IX. Soft tissue &amp; other extraosseous sarcomas</b>		
a. Rhabdomyosarcomas	8900-8905,8910,8912,8920,8991	C000-C809
b. Fibrosarcomas & other fibrous neoplasms	8810,8811,8813-8815,8821,8823,8834-8835 8820,8822,8824-8827,9150,9160,9491,9540- 9571,9580	C000-C399,C440-C768, C809 C000-C809
c. Kaposi sarcomas	9140	C000-C809
d. Other specified soft tissue sarcomas	8587,8710-8713,8806,8831-8833,8836,8840- 8842,8850-8858,8860-8862,8870,8880,8881, 8890-8898,8921,8982,8990,9040-9044,9120- 9125,9130-9133,9135,9136,9141,9142,9161, 9170-9175,9231,9251,9252,9373,9581 8830 8963 9180,9210,9220,9240 9260 9364 9365	C000-C809 C000-C399,C440-C768, C809 C000-C639,C659-C699, C739-C768,C809 C490-C499 C000-C399,C470-C759 C000-C399,C470-C639, C659-C699,C739-C768, C809 C000-C399,C470-C639, C659-C768,C809
e. Unspecified soft tissue sarcomas	8800-8805	C000-C399,C440-C768, C809

(Continued next page...)

Source: Steliarova-Foucher et al., 2005.<sup>10</sup>

Note: \* Diagnostic group/subgroup includes intracranial and intraspinal tumours of benign or uncertain behaviour.

Table A.1 (cont.): International Classification of Childhood Cancer, Third Edition (ICCC-3)

Diagnostic group/subgroup <sup>1</sup>	ICD-O-3 codes <sup>43</sup>	
	Histology	Site
<b>X. Germ cell, trophoblastic &amp; gonadal tumours*</b>		
a. Intracranial & intraspinal germ cell tumours*	9060-9065,9070-9072,9080-9085,9100,9101	C700-C729,C751-C753
b. Malignant extracranial & extragonadal germ cell tumours	9060-9065,9070-9072,9080-9085,9100-9105	C000-C559,C570-C619, C630-C699,C739-C750, C754-C768,C809
c. Malignant gonadal germ cell tumours	9060-9065,9070-9073,9080- 9085,9090,9091,9100,9101	C569,C620-C629
d. Gonadal carcinomas	8010-8041,8050-8075,8082,8120-8122,8130- 8141,8143,8190-8201,8210,8211,8221-8241, 8244-8246,8260-8263,8290,8310,8313,8320, 8323,8380-8384,8430,8440,8480-8490,8504, 8510,8550,8560-8573,9000,9014,9015 8441-8444,8450,8451,8460-8473	C569,C620-C629 C000-C809
e. Other & unspecified malignant gonadal tumours	8590-8671 8000-8005	C000-C809 C569,C620-C629
<b>XI. Other malignant epithelial neoplasms &amp; melanomas</b>		
a. Adrenocortical carcinomas	8370-8375	C000-C809
b. Thyroid carcinomas	8010-8041,8050-8075,8082,8120-8122,8130- 8141,8190,8200,8201,8211,8230,8231,8244- 8246,8260-8263,8290,8310,8320,8323,8430, 8440,8480,8481,8510,8560-8573 8330-8337,8340-8347,8350	C739 C000-C809
c. Nasopharyngeal carcinomas	8010-8041,8050-8075,8082,8083,8120-8122, 8130-8141,8190,8200,8201,8211,8230,8231, 8244-8246,8260-8263,8290,8310,8320,8323, 8430,8440,8480,8481,8500-8576	C110-C119
d. Melanomas	8720-8780,8790	C000-C809
e. Skin carcinomas	8010-8041,8050-8075,8078,8082,8090-8110, 8140,8143,8147,8190,8200,8240,8246,8247, 8260,8310,8320,8323,8390-8420,8430,8480, 8542,8560,8570-8573,8940,8941	C440-C449
f. Other & unspecified carcinomas	8010-8084,8120-8157,8190-8264,8290,8310, 8313-8315,8320-8325,8360,8380-8384,8430- 8440,8452-8454,8480-8586,8588-8589,8940, 8941,8983,9000,9010-9016,9020,9030	C000-C109,C129-C218, C239-C399,C480-C488, C500-C559,C570-C619, C630-C639,C659-C729, C750-C768,C809
<b>XII. Other &amp; unspecified malignant tumours</b>		
a. Other specified malignant tumours	8930-8936,8950,8951,8971-8981,9050-9055, 9110 9363	C000-C809 C000-C399,C470-C759
b. Other unspecified malignant tumours	8000-8005	C000-C218,C239-C399, C420-C559,C570-C619, C630-C639,C659-C699, C739-C750,C754-C809

Source: Steliarova-Foucher et al., 2005.<sup>10</sup>

Note: \* Diagnostic group/subgroup includes intracranial and intraspinal tumours of benign or uncertain behaviour.

## A.2 Data

### A.2.1 Data quality

The quality of data contained in cancer registries is typically evaluated based on numerical indices for the proportion of records which have been morphologically verified (%MV) and the proportion which are based on death certificate only (%DCO).<sup>44</sup> Morphological verification includes diagnoses based on histological verification, exfoliative cytology and haematological examination of peripheral blood, histology of metastasis and autopsy with histology. High values of %MV and low values of %DCO generally indicate better quality data.

Indices of data quality for the APCR are shown in Table A.2. Morphological verification was greater than 95% for all diagnostic groups, apart from tumours of the central nervous system (86%), other and unspecified tumours (86%) and retinoblastoma (88%). Data quality was also high for the subset of intracranial and intraspinal tumours of benign or uncertain behaviour, with 92% of these cases being morphologically verified. The proportion of cases that were identified by death certificate only was consistently low across all diagnostic groups.

**Table A.2: Indices of data quality for the Australian Paediatric Cancer Registry, 1983-2006**

Diagnostic group <sup>a</sup>	Number of Cases	%MV <sup>b</sup>	%DCO <sup>c</sup>
I. Leukaemias, myeloproliferative & myelodysplastic diseases	4,591	99.3	0.1
II. Lymphomas & reticuloendothelial neoplasms	1,374	99.1	0.1
III. Central nervous system & intracranial/intraspinal neoplasms <sup>d</sup>	3,158	85.7	0.2
IV. Neuroblastoma & other peripheral nervous cell tumours	869	96.0	0.1
V. Retinoblastoma	357	87.7	0.3
VI. Renal tumours	735	98.8	0.1
VII. Hepatic tumours	174	96.0	1.7
VIII. Malignant bone tumours	602	98.7	0.0
IX. Soft tissue & other extraosseous sarcomas	820	98.5	0.0
X. Germ cell tumours, trophoblastic tumours & neoplasms of gonads <sup>d</sup>	511	95.1	0.4
XI. Other malignant epithelial neoplasms & melanomas	705	99.0	0.1
XII. Other & unspecified malignant neoplasms	29	86.2	0.0

Notes: 1. Diagnostic groups defined using the International Classification of Childhood Cancers (ICCC-3).<sup>10</sup>  
 2. %MV = percentage of cases that were morphologically verified.  
 3. %DCO = percentage of cases that were based on death certificate only.  
 4. Diagnostic group includes intracranial and intraspinal tumours of benign or uncertain behaviour.

### A.2.2 Data sources

The Australian Paediatric Cancer Registry collected data on the cohort of children diagnosed with cancer in Australia during 1983-2004, with follow-up information on survival available to the end of 2006 (see Section 1.2). As part of this process, cases were matched against the 2006 National Death Index<sup>45</sup> to ensure that details regarding mortality were as accurate and complete as possible. The NDI is maintained by the Australian Institute of Health and Welfare (AIHW) based on data provided by the Registrars of Births, Deaths and Marriages in each State and Territory, and contains a record of all deaths in Australia since 1980.

Underlying mortality rates for all children in Australia that were used in the estimation of relative survival were calculated from national mortality data, sourced from the General Record of Incidence of Mortality (GRIM) books published by the AIHW,<sup>46</sup> combined with estimated resident population data in single years of age obtained from the Australian Bureau of Statistics.<sup>47</sup>

### A.2.3 International comparisons

Differences in survival between Australia and other parts of the world need to be interpreted with caution, as the estimates may be influenced by a number of factors, such as differences in scope, timing, population coverage, data quality and statistical methodology<sup>48</sup> (see Appendix A.3.3, page 43, for further details on the methods for calculating survival). For these reasons, the other countries included for comparison were limited to those for which recent estimates of childhood cancer survival were available, based on a similar methodology to that used in this report. In particular, it should be noted that in the context of childhood cancer there is little difference between observed and relative survival because the underlying expected survival is usually close to 100%.

### A.2.4 Tumour stage

The stage of a tumour is used to describe the extent to which the cancer has progressed. Staging takes into account a variety of factors, which typically include the size of a tumour, the number of lymph nodes involved, and whether the cancer has invaded adjacent organs or spread to distant sites. It is one of the most important predictors of survival and can also be used to determine the most appropriate form of treatment.<sup>49</sup>

Not all types of cancer can be staged. For childhood cancers, stage information is generally available for four of the twelve diagnostic groups, namely lymphomas, neuroblastoma, renal tumours and the diagnostic subgroup of rhabdomyosarcomas (part of the diagnostic group of soft tissue sarcomas).

The broad meaning of the different staging categories for solid tumours can be summarised as follows:

*Stage I* – tumour is localised to the part of the body where it originated without any evidence of spread and has been surgically removed.

*Stage II* – as per Stage I, except that the tumour has been incompletely removed.

*Stage III* – greater regional involvement, preventing surgical resection and often including involvement of lymph nodes.

*Stage IV* – cancer has spread (metastasised) to distant parts of the body, such as the lungs or bone marrow.

However, the details of how a particular stage is defined may vary depending on the type of cancer, particularly for lymphomas compared to solid tumours. Interested readers should refer to the individual classification systems for the specific staging details for each diagnostic group/subgroup:

*Hodgkin lymphomas* – Ann Arbor classification system.<sup>21</sup>

*Non-Hodgkin lymphomas (including Burkitt lymphomas)* – Murphy classification system.<sup>22</sup>

*Neuroblastoma* – International Neuroblastoma Staging System.<sup>26</sup>

*Renal tumours* – Third National Wilms' Tumor Study.<sup>31</sup>

*Rhabdomyosarcoma* – Intergroup Rhabdomyosarcoma Study-I.<sup>38</sup>

## A.3 Methods

### A.3.1 Confidence intervals

The level of accuracy of statistical estimates is typically reported in terms of a confidence interval, which specifies a range of values in which the actual result is expected to occur with a given level of certainty. For example, the 5-year relative survival rate for all children with cancer in Australia who were diagnosed during 1995–2004 was estimated to be 79.5% with a 95% confidence interval of 78.5%–80.5%. This means that there was a 95% probability that the true 5-year relative survival rate was somewhere between 78.5% and 80.5%.

For a given level of probability, a smaller confidence interval indicates a more reliable estimate. The number of cases that an estimate is based on is a major factor in determining the width of the associated confidence interval. Generally speaking, the greater the number of cases involved in calculating an estimate, the smaller the confidence interval will be. Due care should be taken when interpreting estimates which have a wide confidence interval.

### A.3.2 P-values

P-values provide a measure of the likelihood that differences in survival estimates were real or occurred by chance alone. Smaller p-values indicate survival rates that are more likely to be truly different from each other, rather than a result of random variation. An arbitrary cut-off value ( $p < 0.05$ ) has been chosen to determine the statistical significance of comparisons throughout this report. One limitation of this approach is the problem of multiple comparisons, which can inflate the probability of incorrectly identifying the difference between estimates as being statistically significant.

The p-values shown throughout the report were obtained by fitting a Poisson model to the number of deaths within 5 years of diagnosis, offset by the log of the corresponding person years at risk. Models were simultaneously adjusted for sex, age group at diagnosis, year of follow-up and the particular variable of interest (for example, year of diagnosis). Differences between individual estimates (p-values not shown) were only deemed to be significant if the overall effect was also statistically significant.

### A.3.3 Relative survival

#### *Definition*

Observed survival measures the proportion of people who remain alive for a given period of time (typically 5 years) following a diagnosis of cancer. Relative survival is obtained by dividing the observed survival by the expected survival within the general population, taking into account age, sex and year of diagnosis. It is the most commonly presented measure of survival when using data from population-based cancer registries.<sup>50</sup> The main advantage of reporting relative survival is that it does not require information about the specific cause of death, only knowledge of whether or not the patient has died.

#### *Method*

Two approaches are available for calculating relative survival estimates: the traditional cohort method, which follows the same group of patients over time; and the period method, which is based on different groups of patients within an “at risk” window of time. Although the period method tends to produce more up-to-date estimates, particularly for longer-term survival,<sup>51</sup> the cohort method was deemed to be more suitable for the purposes of this report given that it describes the survival experience of a clearly defined group of individuals and is therefore easier for a wider audience to interpret.

The survival of all childhood cancer patients was followed up to the 31st December 2006, and those who were still alive at that date were censored. To avoid bias, patients whose cancer diagnosis was based on death certificate or autopsy only were excluded, as were those with a survival time of zero days or less.

A suite of SAS® computer programs developed by Paul Dickman<sup>52</sup> from the Karolinska Institutet in Sweden was used to generate the relative survival estimates. These programs use a life table (or actuarial) method for calculating observed survival. This approach involves dividing the total time being studied into a series of discrete intervals. Survival probabilities were formulated for each of these intervals, and then multiplied together to produce the observed survival estimate. Expected survival (based on age-specific national mortality data obtained from the Australian Institute of Health and Welfare<sup>46</sup>) was calculated based on the Ederer II method.<sup>53</sup> Three-year averages were used for expected survival to minimise the effects of year to year variation. Relative survival estimates were then obtained from the ratio of observed survival to expected survival.

## A.4 Detailed estimates of survival for childhood cancer diagnostic subgroups

Table A.4a: Five-year relative survival for childhood cancer diagnostic subgroups<sup>a</sup> by sex, Australia, 1995-2004<sup>b</sup>

Diagnostic subgroup	Boys		Girls		p-value
	No. of cases <sup>c</sup>	Five-year relative survival (95% CI) <sup>d</sup>	No. of cases <sup>c</sup>	Five-year relative survival (95% CI) <sup>d</sup>	
Ia. Lymphoid leukaemias	855	82.7 (79.8-85.2)	737	88.2 (85.5-90.5)	<0.001
Ib. Acute myeloid leukaemias	175	62.1 (54.4-68.9)	154	62.5 (54.2-69.7)	0.809
IIa. Hodgkin lymphomas	159	96.2 (91.5-98.4)	81	98.9 (91.6-99.9)	0.206
IIb. Non-Hodgkin lymphomas (excl. Burkitt)	156	83.4 (76.2-88.5)	80	81.0 (70.4-88.1)	0.626
IIc. Burkitt lymphomas	102	89.4 (81.5-94.1)	See footnote f		n.a.
IIIa. Ependymomas and choroid plexus tumours <sup>e</sup>	67	66.1 (53.3-76.1)	62	71.3 (57.6-81.2)	0.575
IIIb. Astrocytomas <sup>e</sup>	348	78.3 (73.6-82.3)	322	77.4 (72.4-81.7)	0.864
IIIc. Intracranial & intraspinal embryonal tumours <sup>e</sup>	156	52.3 (44.1-59.8)	107	48.2 (38.0-57.6)	0.643
IIId. Other gliomas <sup>e</sup>	82	57.0 (45.6-66.8)	82	50.8 (39.2-61.2)	0.595
IIIe/IIIf. Other intracranial & intraspinal neoplasms <sup>e</sup>	95	90.4 (82.3-94.9)	85	93.7 (85.5-97.4)	0.297
IVa. Neuroblastoma & ganglioneuroblastoma	191	66.4 (59.0-72.7)	169	69.4 (61.6-75.9)	0.533
Vla. Nephroblastoma & nonepithelial renal tumours	149	85.0 (78.0-90.0)	169	92.3 (87.0-95.5)	0.069
VIIa. Hepatoblastoma	49	81.5 (67.2-90.1)	29	96.9 (77.8-99.8)	0.124
VIIIa. Osteosarcomas	58	68.7 (54.4-79.3)	64	72.2 (58.9-81.8)	0.858
VIIIc. Ewing tumours & related bone sarcomas	71	66.9 (54.0-77.0)	53	69.2 (53.2-80.7)	0.398
IXa. Rhabdomyosarcomas	94	68.8 (57.7-77.6)	66	67.4 (53.9-77.7)	0.988
IXb/IXc/IXd/IXe. Non-rhabdomyosarcomas	88	69.1 (58.0-77.8)	85	76.2 (65.4-84.1)	0.344
Xa. Intracranial & intraspinal germ cell tumours <sup>e</sup>	43	83.9 (69.0-92.1)	26	84.8 (59.5-95.0)	0.564
Xb. Malign. extracranial/gonadal germ cell tumours	28	93.0 (75.0-98.4)	39	82.3 (66.2-91.3)	0.206
Xc. Malignant gonadal germ cell tumours	55	98.5 (88.0-100.0)	48	100.0 <sup>g</sup> n.a.	n.a.
XIb. Thyroid carcinomas	20	93.8 (61.8-99.3)	36	100.0 <sup>g</sup> n.a.	n.a.
XId. Melanomas	73	96.8 (87.3-99.4)	102	97.1 (91.2-99.1)	0.931
XIa/XIc/XIe/XIf. Other & unspecified carcinomas	48	80.8 (66.3-89.5)	45	83.9 (68.9-92.0)	0.406

Notes: a. Only diagnostic subgroups with a sufficient number of cases for analysis have been included in the table.  
b. Cohort includes children diagnosed during 1995-2004 with follow-up to 31 Dec 2006.  
c. The initial number of eligible cases in the cohort.  
d. 95% CI = 95% confidence interval.  
e. Diagnostic subgroup includes intracranial and intraspinal tumours of benign or uncertain behaviour.  
f. Insufficient number of cases to calculate a separate survival estimate for girls.  
g. Confidence interval (and corresponding p-value) could not be calculated because no deaths were recorded.  
n.a. = not applicable.

**Table A.4b: Five-year relative survival for childhood cancer diagnostic subgroups<sup>a</sup> by age group at diagnosis, Australia, 1995–2004<sup>b</sup>**

Diagnostic subgroup	<1 year old		1-4 years old		5-9 years old		10-14 years old		p-value
	No. of cases <sup>c</sup>	Five-year relative survival (95% CI) <sup>d</sup>	No. of cases <sup>c</sup>	Five-year relative survival (95% CI) <sup>d</sup>	No. of cases <sup>c</sup>	Five-year relative survival (95% CI) <sup>d</sup>	No. of cases <sup>c</sup>	Five-year relative survival (95% CI) <sup>d</sup>	
Ia. Lymphoid leukaemias	46	53.9 (38.4-67.1)	809	89.7 (87.3-91.8)	461	84.3 (80.4-87.4)	276	79.2 (73.6-83.7)	<0.001
Ib. Acute myeloid leukaemias	41	50.1 (33.8-64.5)	110	65.8 (56.1-73.9)	91	64.7 (53.8-73.6)	87	60.8 (49.5-70.4)	0.315
Ila. Hodgkin lymphomas	See footnote f	See footnote f	See footnote f	See footnote f	66	98.3 (88.1-99.8)	174	96.6 (92.5-98.6)	0.305
Ilb. Non-Hodgkin lymphomas (excl. Burkitt)	See footnote f	See footnote f	59	82.0 (69.1-89.9) <sup>†</sup>	76	82.3 (71.3-89.5)	70	83.1 (74.2-89.2)	0.999
Ilc. Burkitt lymphomas	See footnote f	See footnote f	27	92.7 (73.6-98.2) <sup>†</sup>	53	85.2 (72.2-92.5)	39	95.0 (81.1-98.8)	0.243
Ili. Ependymomas and choroid plexus tumours <sup>e</sup>	See footnote f	See footnote f	72	59.4 (46.8-69.9)	34	72.6 (53.7-84.8)	23	91.1 (67.4-97.9)	0.009
Iliib. Astrocytomas <sup>e</sup>	37	63.7 (46.6-76.7)	229	78.5 (72.5-83.3)	214	79.6 (73.4-84.5)	190	77.9 (71.2-83.2)	0.205
Iliic. Intracranial & intraspinal embryonal tumours <sup>e</sup>	23	2.5 (0.2-11.4)	96	39.6 (29.9-49.2)	92	66.2 (54.9-75.3)	52	64.3 (49.0-76.1)	<0.001
Iliid. Other gliomas <sup>e</sup>	See footnote f	See footnote f	51	60.2 (45.4-72.2) <sup>†</sup>	66	45.7 (33.0-57.5)	47	59.2 (43.8-71.7)	0.125
Iliie/Iliif. Other intracranial & intraspinal neoplasms <sup>e</sup>	See footnote f	See footnote f	49	84.7 (70.4-92.4) <sup>†</sup>	59	93.2 (83.0-97.4)	72	96.0 (87.8-98.8)	0.119
Iv. Neuroblastoma & ganglioneuroblastoma	152	84.5 (77.6-89.5)	174	57.1 (49.1-64.2)	34	48.8 (31.0-64.4) <sup>†</sup>	See footnote f	See footnote f	<0.001
V. Nephroblastoma & nonepithelial renal tumours	40	77.7 (60.7-88.1)	204	92.0 (87.3-95.1)	74	86.4 (76.1-92.5) <sup>†</sup>	See footnote f	See footnote f	0.066
Vla. Hepatoblastoma	34	91.6 (75.6-97.6)	35	91.8 (75.7-97.5)	See footnote g	See footnote g	See footnote g	See footnote g	1.000
Vliia. Osteosarcomas	See footnote g	See footnote g	See footnote g	See footnote g	22	90.9 (68.4-97.7)	95	66.3 (55.3-75.2)	0.069
Vliic. Ewing tumours & related bone sarcomas	See footnote f	See footnote f	21	65.5 (39.9-82.3)	38	83.1 (65.9-92.1)	65	59.6 (45.1-71.6)	0.074
Ix. Rhabdomyosarcomas	See footnote f	See footnote f	82	75.4 (63.4-83.7)	49	70.1 (55.1-81.9)	29	43.8 (24.4-61.7)	0.034
Ixb./Ixc./Ixd./Xe. Non-rhabdomyosarcomas	See footnote f	See footnote f	41	72.8 (56.4-83.9) <sup>†</sup>	41	72.1 (54.9-83.7)	91	72.5 (61.8-80.7)	0.953
Xa. Intracranial & intraspinal germ cell tumours <sup>e</sup>	See footnote f	See footnote f	21	85.6 (62.3-95.1)	See footnote f	See footnote f	48	84.4 (69.6-92.4)	0.895
Xb. Malign. extracranial/gonadal germ cell tumours	36	86.3 (70.1-94.2)	22	90.8 (68.6-97.6)	See footnote g	See footnote g	See footnote g	See footnote g	0.715
Xc. Malignant gonadal germ cell tumours	See footnote f	See footnote f	47	98.2 (86.1-100.0) <sup>†</sup>	See footnote f	See footnote f	56	100.0 <sup>h</sup>	n.a.
Xib. Thyroid carcinomas	See footnote g	See footnote g	See footnote g	See footnote g	See footnote g	See footnote g	41	97.2 (81.1-99.7)	n.a.
Xid. Melanomas	See footnote g	See footnote g	See footnote g	See footnote g	30	100.0 <sup>h</sup>	135	96.1 (90.6-98.5)	n.a.
Xia/Xic/Xie/Xif. Other & unspecified carcinomas	See footnote g	See footnote g	See footnote g	See footnote g	See footnote g	See footnote g	70	86.8 (76.0-93.0)	n.a.

Notes: a. Only diagnostic subgroups with a sufficient number of cases for analysis have been included in the table.

b. Cohort includes children diagnosed between 1995-2004 with follow-up to 31 Dec 2006.

c. The initial number of eligible cases in the cohort.

d. 95% CI = 95% confidence interval.

e. Diagnostic subgroup includes intracranial and intraspinal tumours of benign or uncertain behaviour.

f. The following age groups were combined for the specified diagnostic subgroups due to the small number of cases: "0-4 years old" for Non-Hodgkin lymphomas (excl. Burkitt), Burkitt lymphomas, ependymomas and choroid plexus tumours, other gliomas, other intracranial & intraspinal neoplasms, Ewing tumours & related bone sarcomas, rhabdomyosarcomas, non-rhabdomyosarcoma soft tissue sarcomas, intracranial & intraspinal germ cell tumours, malignant gonadal germ cell tumours; "0-9 years old" for Hodgkin lymphomas; and "5-14 years old" for neuroblastoma & ganglioneuroblastoma, nephroblastoma & nonepithelial renal tumours, intracranial & intraspinal germ cell tumours, malignant gonadal germ cell tumours.

g. There were an insufficient number of cases to calculate survival estimates for children aged 0-4 years who were diagnosed with osteosarcomas or melanomas, children aged 0-9 years who were diagnosed with thyroid carcinomas or other & unspecified carcinomas and children aged 5-14 years who were diagnosed with hepatoblastoma or malignant extracranial & extragonadal germ cell tumours.

h. Confidence interval (and corresponding p-value) could not be calculated because no deaths were recorded.

n.a. = not applicable.

**Table A.4c: Five-year relative survival for childhood cancer diagnostic subgroups<sup>a</sup> by tumour stage<sup>b</sup>, Australia, 1995-2004<sup>c</sup>**

Diagnostic subgroup	Stage I		Stage II		Stage III		Stage IV	
	No. of cases <sup>d</sup>	Five-year relative survival (95% CI) <sup>e</sup>	No. of cases <sup>d</sup>	Five-year relative survival (95% CI) <sup>e</sup>	No. of cases <sup>d</sup>	Five-year relative survival (95% CI) <sup>e</sup>	No. of cases <sup>d</sup>	Five-year relative survival (95% CI) <sup>e</sup>
Ila. Hodgkin lymphomas	79	100.0 <sup>f</sup> n.a.	82	98.7 (90.7-99.9)	53	88.3 (75.7-94.7) <sup>g</sup>	27	80.0 (58.2-91.3)
Ilb. Non-Hodgkin lymphomas (excl. Burkitt)	38	89.5 (74.1-96.0)	26	88.6 (68.4-96.2)	87	80.2 (70.0-87.2)	20	90.3 (65.4-97.6)
Ilc. Burkitt lymphomas	See footnote g	See footnote g	34	97.2 (80.9-99.7) <sup>h</sup>	50	86.3 (73.0-93.3)	188	49.8 (42.3-56.9)
Iva. Neuroblastoma & ganglioneuroblastoma	68	95.6 (86.5-98.8)	44	90.9 (77.0-96.8)	46	73.3 (57.4-84.1)	70	74.0 (61.9-82.8)
Via. Nephroblastoma & nonepithelial renal tumours	70	97.3 (89.0-99.5)	76	92.7 (83.1-97.0)	78	92.4 (83.7-96.6)	59	53.0 (39.1-65.0)
IXa. Rhabdomyosarcomas	See footnote g	See footnote g	68	83.0 (71.3-90.3)	See footnote g	See footnote g	See footnote g	<0.001

Notes: a. Only diagnostic subgroups with a sufficient number of cases for analysis and for which staging information was available have been included in the table.

b. The Ann Arbor classification system<sup>22</sup> was used to stage Hodgkin lymphomas; the Murphy classification system<sup>23</sup> was used to stage non-Hodgkin lymphomas; the International Neuroblastoma Staging System<sup>27</sup> was used to stage neuroblastoma; the Third National Wilms' Tumor Study classification system<sup>32</sup> was used to stage nephroblastoma & nonepithelial renal tumours, and the Intergrupp

c. Cohort includes children diagnosed between 1995-2004 with follow-up to 31 Dec 2006. Rhabdomyosarcoma Study-I<sup>39</sup> was used to stage rhabdomyosarcomas.

d. The initial number of eligible cases in the cohort.

e. 95% CI = 95% confidence interval.

f. Confidence interval could not be calculated because no deaths were recorded.

g. The following stage groups were combined for the specified diagnostic subgroups due to the small number of cases: "Stages I/II" for Burkitt lymphomas and rhabdomyosarcomas; and "Stages III/IV" for Hodgkin lymphomas and rhabdomyosarcomas.

n.a. = not applicable.

**Table A.4d: Five-year relative survival for childhood cancer diagnostic subgroups<sup>a</sup> by year of diagnosis, Australia, 1983-2004<sup>b</sup>**

Diagnostic subgroup	1983-1994		1995-2004		p-value
	No. of cases <sup>c</sup>	Five-year relative survival (95% CI) <sup>d</sup>	No. of cases <sup>c</sup>	Five-year relative survival (95% CI) <sup>d</sup>	
Ia. Lymphoid leukaemias	1,676	75.5 (73.4-77.5)	1,592	85.3 (83.3-87.0)	<0.001
Ib. Acute myeloid leukaemias	355	44.1 (38.9-49.2)	329	62.3 (56.7-67.3)	<0.001
IIa. Hodgkin lymphomas	223	94.8 (90.9-97.1)	240	97.1 (93.8-98.7)	0.222
IIb. Non-Hodgkin lymphomas (excl. Burkitt)	289	75.9 (70.6-80.5)	236	82.6 (76.9-86.9)	0.069
IIc. Burkitt lymphomas	88	73.5 (62.7-81.6)	119	90.1 (83.1-94.3)	0.002
IIIa. Ependymomas and choroid plexus tumours <sup>e</sup>	149	66.5 (58.3-73.4)	129	68.6 (59.6-76.0)	0.672
IIIb. Astrocytomas <sup>e</sup>	666	77.3 (73.9-80.3)	670	77.9 (74.5-80.9)	0.779
IIIc. Intracranial & intraspinal embryonal tumours <sup>e</sup>	272	49.5 (43.4-55.2)	263	50.5 (44.2-56.5)	0.979
IIId. Other gliomas <sup>e</sup>	175	48.5 (40.9-55.8)	164	53.8 (45.8-61.2)	0.435
IIIe/III f. Other intracranial & intraspinal neoplasms <sup>e</sup>	175	80.0 (73.3-85.2)	180	92.0 (86.8-95.2)	0.003
IVa. Neuroblastoma & ganglioneuroblastoma	397	51.4 (46.3-56.2)	360	67.8 (62.6-72.4)	<0.001
VIa. Nephroblastoma & nonepithelial renal tumours	331	87.5 (83.4-90.7)	318	88.9 (84.8-92.0)	0.627
VIIa. Hepatoblastoma	45	82.6 (67.9-91.1)	56	87.1 (77.1-93.1)	0.247
VIIIa. Osteosarcomas	114	64.8 (55.3-72.8)	122	70.6 (61.2-78.1)	0.291
VIIIc. Ewing tumours & related bone sarcomas	153	64.4 (56.2-71.4)	124	67.8 (58.0-75.8)	0.417
IXa. Rhabdomyosarcomas	232	64.8 (58.3-70.6)	160	68.2 (59.9-75.2)	0.179
IXb/IXc/IXd/IXe. Non-rhabdomyosarcomas	179	84.5 (78.3-89.1)	173	72.5 (65.0-78.6)	0.007
Xa. Intracranial & intraspinal germ cell tumours <sup>e</sup>	58	75.9 (62.7-85.0)	69	84.5 (72.8-91.5)	0.179
Xb. Malign. extracranial/gonadal germ cell tumours	49	84.1 (70.3-91.9)	67	86.8 (76.0-93.0)	0.766
Xc. Malignant gonadal germ cell tumours	86	93.3 (85.3-97.1)	103	99.2 (93.5-100.0)	0.226
XIb. Thyroid carcinomas	45	95.7 (83.5-99.0)	56	97.9 (85.9-99.8)	0.515
XId. Melanomas	200	92.9 (88.4-95.8)	175	97.0 (92.8-98.8)	0.063
XIa/XIc/XIe/XIf. Other & unspecified carcinomas	81	78.0 (67.3-85.6)	93	82.2 (72.6-88.8)	0.544

Notes: a. Only diagnostic subgroups with a sufficient number of cases for analysis have been included in the table.  
 b. Cohorts include children diagnosed during 1983-1994 and 1995-2004 with follow-up to 31 Dec 2006.  
 c. The initial number of eligible cases in the cohort.  
 d. 95% CI = 95% confidence interval.  
 e. Diagnostic subgroup includes intracranial and intraspinal tumours of benign or uncertain behaviour.

## References

1. Youlden D, Baade P, Ward L, et al., 2009. *Childhood cancer incidence in Australia, 1983-2006*. Viertel Centre for Research in Cancer Control, Cancer Council Queensland and the Australian Paediatric Cancer Registry: Brisbane, Queensland.
2. Australian Institute of Health and Welfare, 2009. *Australian Cancer Incidence and Mortality (ACIM) Books*. AIHW: Canberra. Retrieved 18 May 2010, from [www.aihw.gov.au/cancer/data/acim\\_books/index.cfm](http://www.aihw.gov.au/cancer/data/acim_books/index.cfm).
3. Australian Institute of Health and Welfare, 2009. *A picture of Australia's children 2009*. Cat. No. PHE 112. AIHW: Canberra.
4. Hewitt M, Weiner S, Simone J, eds. 2003. *Childhood cancer survivorship: improving care and quality of life*. National Academies Press: Washington, DC.
5. O'Leary M, Krailo M, Anderson JR, et al., 2008. Progress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology Group. *Semin Oncol*, 35(5):484-493.
6. Bond MC, Pritchard S, 2006. Understanding clinical trials in childhood cancer. *Paediatr Child Health*, 11(3):148-150.
7. Pizzo P, Poplack D, eds. 2006. *Principles and Practice of Pediatric Oncology*, 5th edition. Lippincott, Williams & Wilkins: Philadelphia.
8. Landier W, Bhatia S, 2008. Cancer survivorship: a pediatric perspective. *Oncologist*, 13(11):1181-1192.
9. Lenhard R, Osteen R, Gansler T, eds. 2001. *Clinical Oncology*. American Cancer Society: Atlanta, GA.
10. Steliarova-Foucher E, Stiller C, Lacour B, et al., 2005. International Classification of Childhood Cancer, third edition. *Cancer*, 103(7):1457-1467.
11. Stiller CA, 2004. Epidemiology and genetics of childhood cancer. *Oncogene*, 23(38):6429-6444.
12. Gatta G, Zigon G, Capocaccia R, et al., 2009. Survival of European children and young adults with cancer diagnosed 1995-2002. *Eur J Cancer*, 45(6):992-1005.
13. Desandes E, Berger C, Tron I, et al., 2008. Childhood cancer survival in France, 1990-1999. *Eur J Cancer*, 44(2):205-215.
14. Childhood Cancer Research Group, 2010. *Survival from childhood cancer, Great Britain, 1971-2005*. Retrieved 12 July 2010, from [www.ccr.g.ox.ac.uk/datasets/survivalrates.htm](http://www.ccr.g.ox.ac.uk/datasets/survivalrates.htm).
15. Altekruse S, Kosary C, Krapcho M, et al., 2010. *SEER Cancer Statistics Review, 1975-2007*. National Cancer Institute: Bethesda, MD.
16. Colby-Graham MF, Chordas C, 2003. The childhood leukemias. *J Pediatr Nurs*, 18(2):87-95.
17. Hutter JJ. Childhood leukemia. *Pediatr Rev*, 31(6):234-241.
18. Freed J, Kelly KM, 2010. Current approaches to the management of pediatric Hodgkin lymphoma. *Paediatr Drugs*, 12(2):85-98.
19. Pinkerton R, 2005. Continuing challenges in childhood non-Hodgkin's lymphoma. *Br J Haematol*, 130(4):480-488.
20. Reiter A, 2007. Diagnosis and treatment of childhood non-Hodgkin lymphoma. *Hematology Am Soc Hematol Educ Program*:285-296.
21. Carbone PP, Kaplan HS, Musshoff K, et al., 1971. Report of the Committee on Hodgkin's Disease Staging Classification. *Cancer Res*, 31(11):1860-1861.
22. Murphy SB, Fairclough DL, Hutchison RE, et al., 1989. Non-Hodgkin's lymphomas of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution. *J Clin Oncol*, 7(2):186-193.
23. McKinney PA, 2005. Central nervous system tumours in children: epidemiology and risk factors. *Bioelectromagnetics*, Suppl 7:560-68.
24. Wilne S, Collier J, Kennedy C, et al., 2007. Presentation of childhood CNS tumours: a systematic review and meta-analysis. *Lancet Oncol*, 8(8):685-695.
25. Papaioannou G, McHugh K, 2005. Neuroblastoma in childhood: review and radiological findings. *Cancer Imaging*, 5:116-127.
26. Brodeur GM, Pritchard J, Berthold F, et al., 1993. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. *J Clin Oncol*, 11(8):1466-1477.
27. Wilson WG, 2007. Retinoblastoma. *Pediatr Rev*, 28(1):37-38.
28. Poulaki V, Mukai S, 2009. Retinoblastoma: genetics and pathology. *Int Ophthalmol Clin*, 49(1):155-164.
29. Sebire NJ, Vujanac GM, 2009. Paediatric renal tumours: recent developments, new entities and pathological features. *Histopathology*, 54(5):516-528.
30. Varan A, 2008. Wilms' tumor in children: an overview. *Nephron Clin Pract*, 108(2):c83-90.

31. D'Angio GJ, Breslow N, Beckwith JB, et al., 1989. Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study. *Cancer*, 64(2):349-360.
32. Litten JB, Tomlinson GE, 2008. Liver tumors in children. *Oncologist*, 13(7):812-820.
33. Meyers RL, 2007. Tumors of the liver in children. *Surg Oncol*, 16(3):195-203.
34. Eyre R, Feltbower RG, Mubwandarikwa E, et al., 2009. Epidemiology of bone tumours in children and young adults. *Pediatr Blood Cancer*, 53(6):941-952.
35. Meyer WH, Spunt SL, 2004. Soft tissue sarcomas of childhood. *Cancer Treat Rev*, 30(3):269-280.
36. Loeb DM, Thornton K, Shokek O, 2008. Pediatric soft tissue sarcomas. *Surg Clin North Am*, 88(3):615-627.
37. Spunt SL, Skapek SX, Coffin CM, 2008. Pediatric nonrhabdomyosarcoma soft tissue sarcomas. *Oncologist*, 13(6):668-678.
38. Maurer HM, Beltangady M, Gehan EA, et al., 1988. The Intergroup Rhabdomyosarcoma Study-I. A final report. *Cancer*, 61(2):209-220.
39. Horton Z, Schlatter M, Schultz S, 2007. Pediatric germ cell tumors. *Surg Oncol*, 16(3):205-213.
40. Billmire DF, 2006. Malignant germ cell tumors in childhood. *Semin Pediatr Surg*, 15(1):30-36.
41. Downard CD, Rapkin LB, Gow KW, 2007. Melanoma in children and adolescents. *Surg Oncol*, 16(3):215-220.
42. Pappo AS, 2003. Melanoma in children and adolescents. *Eur J Cancer*, 39(18):2651-2661.
43. Fritz A, Percy C, Jack A, et al., eds. 2000. International Classification of Diseases for Oncology. 3rd edition. World Health Organization: Geneva.
44. Parkin DM, Bray F, 2009. Evaluation of data quality in the cancer registry: principles and methods. Part II - completeness. *Eur J Cancer*, 45(5):756-764.
45. Australian Institute of Health and Welfare, 2006. *National Death Index*. Retrieved 20 Aug 2010, from [www.aihw.gov.au/cancer/ndi/index.cfm](http://www.aihw.gov.au/cancer/ndi/index.cfm).
46. Australian Institute of Health and Welfare, 2008. *State and Territories GRIM (General Record of Incidence of Mortality) Books*. AIHW: Canberra. Retrieved 27 May 2010, from [www.aihw.gov.au/mortality/data/grim\\_books\\_national.cfm](http://www.aihw.gov.au/mortality/data/grim_books_national.cfm).
47. Australian Bureau of Statistics, 2008. *Population by Age and Sex, Australian States and Territories, June 2008*. ABS Cat. No. 3201.0. ABS: Canberra. Retrieved 8 April 2009, from [www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/3201.0Main+Features1Jun%202008?OpenDocument](http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/3201.0Main+Features1Jun%202008?OpenDocument).
48. Coleman MP, Quaresma M, Berrino F, et al., 2008. Cancer survival in five continents: a worldwide population-based study (CONCORD). *Lancet Oncol*, 9(8):730-756.
49. Gospodarowicz M, Benedet L, Hutter RV, et al., 1998. History and international developments in cancer staging. *Cancer Prev Control*, 2(6):262-268.
50. Dickman PW, Sloggett A, Hills M, et al., 2004. Regression models for relative survival. *Stat Med*, 23(1):51-64.
51. Brenner H, Gefeller O, Hakulinen T, 2004. Period analysis for 'up-to-date' cancer survival data: theory, empirical evaluation, computation realisation and applications. *Eur J Cancer*, 40:326-335.
52. Dickman PW, 2004. *Estimating and modelling relative survival using SAS*. Retrieved 24 July 2007, from [www.pauldickman.com/rsmodel/sas\\_colon/](http://www.pauldickman.com/rsmodel/sas_colon/).
53. Ederer F, Axtell LM, Cutler SJ, 1961. The relative survival rate: a statistical methodology. *NCI Monogr*, 6:101-121.